UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

o		REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

þ		ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2006

OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

o		SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report                     

(Exact name of Registrant as specified in its charter)

Not Applicable

Republic of France

Parc Club du Moulin a Vent
33, avenue du Docteur Georges Levy
69693 Vénissieux Cedex France

Securities registered or to be registered pursuant to Section 12(b) of the Act.

		Name of Exchange
Title of each class		on which Registered
Ordinary Shares, nominal value 0.122 Euros per share, represented by American Depositary Shares (as evidenced by American Depositary Receipts), each representing one Ordinary Share		NASDAQ Global Market

Securities registered or to be registered pursuant to Section 12(g) of the Act. None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None.

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

[update] 23,990,590 Ordinary Shares, nominal value 0.122 Euros per Ordinary Share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes o      No þ

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes o      No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ      No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer o      Accelerated filer þ      Non-accelerated filer o

Indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 o      Item 18 þ

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o      No þ

 

 

TABLE OF CONTENTS

PART I			1
ITEM 1. Identity of Directors, Senior Management and Advisers			1
ITEM 2. Offer Statistics and Expected Timetable			1
ITEM 3. Key Information			1
ITEM 4. Information on the Company			11
ITEM 4A. Unresolved Staff Comments			31
ITEM 5. Operating and Financial Review and Prospects			31
ITEM 6. Directors, Senior Management and Employees			38
ITEM 7. Major Shareholders and Related Party Transactions			47
ITEM 8. Financial Information			48
ITEM 9. The Offer and Listing			49
ITEM 10. Additional Information			49
ITEM 11. Quantitative and Qualitative Disclosures About Market Risk			56
ITEM 12. Description of Securities Other Than Equity Securities			56
PART II			57
ITEM 13. Defaults, Dividend Arrearages and Delinquencies			57
ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds			57
ITEM 15. Controls and Procedures			57
ITEM 16. [Reserved]			58
ITEM 16C. Principal Accountant Fees and Services			58
ITEM 16D. Exemptions from the Listing Standards for Audit Committees			59
ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers			59
PART III			60
ITEM 17. Financial Statements			60
ITEM 18. Financial Statements			60
ITEM 19. Exhibits			60

     As used herein, references to the Company, ‘we,’ ‘us,’ ‘our,’ the Registrant and Flamel refer to Flamel Technologies S.A. and its consolidated subsidiary, Flamel Technologies, Inc., unless the context indicates otherwise. References to Shares herein refer to (i) the Ordinary Shares of Flamel, nominal value 0.122 Euros per Ordinary Share (the ‘Ordinary Shares’) and (ii) Flamel’s American Depositary Shares, each of which represents one Ordinary Share (‘ADSs’). The ADSs are evidenced by American Depositary Receipts (‘ADRs’). Ordinary Shares and ADSs are referred to herein as ‘Shares.’

     The following product or technology designations are trademarks of the Company: Asacard^®, Basulin™, Flamel Technologies™, Genvir^TM , Micropump^®, Medusa^®, Trigger Lock™.

     Flamel publishes its financial statements in U.S. dollars. In this annual report, references to ‘dollars’ or ‘$’ are to U.S. dollars and references to ‘Euros’ or ‘EUR’ are to the currency of the European Union as used in the Republic of France. Except as otherwise stated herein, all monetary amounts in this annual report have been presented in dollars. Solely for the convenience of the reader, this annual report contains translations of certain Euro amounts into dollars at specified rates. See ‘Item 3. Key Information — Exchange Rates’ for information regarding the rates of exchange between the Euro and the dollar in each of the previous five years.

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

     This annual report contains forward-looking statements. We may make additional written or oral forward-looking statements from time to time in filings with the Securities and Exchange Commission or otherwise. The words ‘believe,’ ‘expect,’ ‘anticipate,’ ‘project’ and similar expressions identify forward-looking statements, which speak only as of the date the statement is made. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although we believe that our expectations are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and there can be no assurance that actual results of our development and manufacturing activities and our results of operations will not differ materially from our expectations. Factors that could cause actual results to differ from expectations include, among others:

	•		our products and product candidates, if approved for marketing, may not produce significant revenues and we rely on our partners to determine the regulatory and marketing strategies;
	•		our products and product candidates, in commercial use, may have unintended side effects, adverse reactions or incidents of misuse;
	•		we may enter into a collaboration with a third party to market or fund a proprietary product candidate and the terms of such a collaboration may not meet our expectations;
	•		our delivery technologies or product development efforts may not produce safe, effective or commercially viable products;
	•		our collaborators could elect to terminate or delay programs at any time and disputes with collaborators or failure to negotiate acceptable new collaborative arrangements for our technologies could occur;
	•		we may be unable to manufacture or, if our products are successful, scale-up the manufacturing of our products economically or on a commercial scale;
	•		unexpected events could interrupt manufacturing operations at our facilities, which could be the sole source of supply for these products;
	•		after the completion of clinical trials of products incorporating our technologies and the submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA), for marketing approval and to other health authorities as a marketing authorization application, the FDA or other health authorities could refuse to accept such filings or could request additional pre-clinical or clinical studies be conducted, each of which could result in significant delays, or such authorities could refuse to approve the product at all;
	•		our product candidates could be ineffective or unsafe during pre-clinical studies and clinical trials and we and our collaborators may not be permitted by regulatory authorities to undertake new or additional clinical trials for product candidates incorporating our technologies, or clinical trials could be delayed;
	•		we may experience significant delays in clinical trials on our products;
	•		we may not realize any revenue from milestone or royalty payments under our license agreements with our partners, including GlaxoSmithKline;
	•		even if our product candidates appear promising at an early stage of development, product candidates could fail to receive necessary regulatory approvals, be difficult to manufacture on a large scale, be uneconomical, fail to achieve market acceptance, be precluded from commercialization by proprietary rights of third parties or experience substantial competition in the marketplace;

	•		technological changes in the biotechnology or pharmaceutical industries could render our product candidates obsolete or noncompetitive;
	•		we may face difficulties or set-backs in obtaining and enforcing our patents or defending claims of patent infringement by others; and
	•		we may need to raise substantial additional funding to continue research and development programs and clinical trials and could incur difficulties or setbacks in raising such funds.

     Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward-looking statements. Statements in this annual report including those set forth in ‘Risk Factors’ in this report, describe factors, among others, that could contribute to or cause such differences.

PART I

          ITEM 1. Identity of Directors, Senior Management and Advisers

     Not applicable.

          ITEM 2. Offer Statistics and Expected Timetable

     Not applicable.

          ITEM 3. Key Information

Selected Financial Data

     The selected consolidated financial data as at and for each of the five years in the period ended December 31, 2006 are derived from the Consolidated Financial Statements of the Company, which have been prepared in accordance with U.S. GAAP and audited by Ernst & Young Audit, independent registered accounting firm with the Public Company Accounting Oversight Board (United States). The selected consolidated financial data of the Company set forth below are qualified by reference to, and should be read in conjunction with, ‘Item 5. Operating and Financial Review and Prospects’ and the Consolidated Financial Statements and the Notes related thereto appearing elsewhere in this annual report.

Statement of Operations Data: *

		2002				2003				2004				2005				2006
Revenues		$	18,406			$	25,167			$	55,410			$	23,598			$	23,020
Cost and Expenses			(18,629	)			(29,866	)			(46,575	)			(64,367	)			(61,858)	**
Income (Loss) from Operations			(223	)			(4,699	)			8,835				(40,769	)			(38,838	)
Interest and foreign exchange gain (loss), net			149				(856	)			363				4,103				1,388
Other income			2,525				1,128				100				5,003				131
Income (loss) before income tax			2,452				(4,427	)			9,298				(31,663	)			(37,319	)
Income tax benefit (expense)			553				503				3,201				4,286				2,118
Net income (loss)		$	3,005			$	(3,924	)		$	12,499			$	(27,377	)		$	(35,201	)
Basic earnings (loss) per ordinary share		$	0.19			$	(0.22	)		$	0.58			$	(1.19	)		$	(1.48	)
Diluted earnings (loss) per ordinary share		$	0.18			$	(0.22	)		$	0.53			$	(1.19	)		$	(1.48	)
Basic weighted average number of shares outstanding (in thousands)			16,198				17,762				21,514				22,999				23,812
Diluted weighted average number of shares outstanding (in thousands)			16,711				17,762				23,559				22,999				23,812
Dividends per share			—				—				—				—				—

Balance Sheet Data: *

		2002				2003				2004				2005				2006
Cash, Cash equivalents & Marketable securities		$	14,527			$	109,617			$	105,374			$	83,774			$	62,771
Working capital**			12,202				102,867				97,446				67,092				55,465
Total assets			23,076				127,252				145,608				124,351				114,894
Long term liabilities (excluding deferred revenues)			2,329				3,123				4,665				12,801				20,504
Shareholders equity			12,286				92,061				116,757				86,654				73,026

Exchange Rates:

     Flamel publishes its financial statements in dollars. However, currently a significant portion of the Company’s expenses are denominated in Euros. For information regarding the effects of currency fluctuations on the Company’s results, see ‘Item 5. Operating and Financial Review and Prospects.’

     The following table sets forth the high, low and average exchange rates for the Euro against the U.S. dollar in each of the last five years and in each of the previous six months.

Year Ended December 31,
Euro to U.S. Dollar:		High				Low				Average Rate1
2006			1.3331				1.1826				1.25567
2005			1.3507				1.1667				1.24478
2004			1.367				1.176				1.248
2003			1.246				1.036				1.132
2002			1.0485				0.8594				0.9495

Previous Six Months,
Euro to U.S. Dollar:		High				Low				Average Rate1
March, 2007			1.3352				1.3083				1.324186
February, 2007			1.323				1.2925				1.30742
January, 2007			1.327				1.2893				1.299864
December, 2006			1.3331				1.3095				1.321279
November, 2006			1.32				1.2702				1.288141
October, 2006			1.2737				1.2515				1.261105

     The exchange rate for the Euro against the U.S. dollar as of April 25, 2007 was $1.3649 to € 1.00. The Company makes no representation that Euro amounts have been, could have been or could be converted into dollars at any of the exchange rates referred to herein as of a given date.

Risk Factors:

     Certain statements made in this annual report on Form 20-F are forward-looking statements based on our current expectations, assumptions, estimates and projections about our business and our industry. These forward-looking statements involve risks and uncertainties. Our business, financial condition and results of operations could differ materially from those anticipated in these forward-looking statements as a result of certain factors, as more fully described below and elsewhere in this annual report. The risks and uncertainties described below are not the only ones we face.

We depend on a few customers for the majority of our revenues, and the loss of any one of these customers could reduce our revenues significantly.

     We depend on a few customers and partners for the majority of our revenues, particularly GlaxoSmithKline. The termination of our relationship with any of these major customers or partners and our failure to broaden our customer base, could cause our revenues to decrease significantly and result in losses from our operations. Further, we may be unable to negotiate favorable business terms with customers and partners that represent a significant portion of our revenues. If so, our revenues and gross profits, if any, may not grow as expected or may not grow at a rate sufficient to allow us to enjoy profitability.

Our revenues depend on pharmaceutical and biotechnology companies successfully developing products that incorporate our drug delivery technologies.

     We market and sell our technologies to third parties, who incorporate our technologies into their products. We depend upon collaborative agreements with pharmaceutical and biotechnology companies to develop, test, obtain regulatory approval for and commercialize products that incorporate our drug delivery technologies. We currently have collaborative agreements or relationships with GlaxoSmithKline, Servier, Merck, and other unnamed pharmaceutical and biotechnology companies.

     The number of products that our partners successfully develop under these collaborative agreements will affect our revenues. We cannot control the timing and other aspects of the development or marketing by our pharmaceutical and biotechnology company partners of their products that incorporate our technologies. The failure of one or more of our partners to develop successful products that incorporate our technologies or to perform as we expect under our agreements with them could have a material and adverse impact on our revenues and profits. We face risks relating to our collaborative agreements, including risks that:

	•		our collaborative agreements may not result in any new commercial products;
	•		the existing commercial products developed under our collaborative agreements may not be successful;
	•		our pharmaceutical and biotechnology company partners may not successfully market any commercial products;
	•		we may not be able to meet the milestones established in our current or future collaborative agreements;
	•		we may not be able to successfully develop new drug delivery technologies that would be attractive to potential pharmaceutical or biotechnology company partners; and
	•		our collaborative partners may terminate their relationships with us.

Although products that incorporate our drug delivery technologies may appear promising at their early stages of development and in clinical trials, none of these potential products may reach the commercial market for a number of reasons.

     Successful research and development of pharmaceutical products is difficult, expensive, and time consuming. Many product candidates fail to reach the market. Accordingly, it is possible that products that incorporate our technologies may never reach the commercial market for any number of reasons. We intend to continue to enhance our current technologies and pursue additional proprietary drug delivery technologies. Our success will depend on the discovery and the successful commercialization of products that can utilize our drug delivery technologies. If products using our technologies fail to reach the commercial market, our revenues would be adversely affected, and we may be unable to increase our revenue.

     Even if our technologies appear promising during various stages of development, there may not be successful commercial applications developed for them because:

	•		the FDA or an institutional review board may delay or stop the conduct of clinical trials;
	•		our pharmaceutical or biotechnology partners may face slower than expected rate of patient recruitment and enrollment;
	•		they may be found to be ineffective or cause harmful side effects, or they may fail during pre-clinical testing or clinical trials;
	•		we may not find pharmaceutical or biotechnology companies to adopt the technologies or, if partnered, the business strategy of our partner may change;
	•		our pharmaceutical and biotechnology company partners may find that certain products cannot be manufactured on a commercial scale and, therefore, may not be economical to produce; or
	•		products that use our technologies also could fail to achieve market acceptance or be precluded from commercialization by proprietary rights of third parties.

We depend on key personnel to execute our business plan. If we cannot attract and retain key personnel, we may not be able to successfully implement our business plan.

     Our success depends in large part upon our ability to attract and retain highly qualified personnel. During our operating history, we have assigned many key responsibilities within our company to a relatively small number of individuals, each of whom has played key roles in executing various important components of our business. We do not maintain material key person life insurance for any of our key personnel. If we lose the services of Stephen H. Willard , our Chief Executive Officer, Michel Finance, our Chief Financial Officer, or Rafael Jorda, our Chief Operating Officer, we may have difficulty executing our business plan in the manner we currently anticipate. Further, because each of our key personnel plays more than one role in respect of numerous components of our business, the loss of any one or more of such individuals could have an adverse effect on our business.

Products that incorporate our drug delivery technologies are subject to regulatory approval. If our pharmaceutical and biotechnology company partners do not obtain such approvals, or if such approvals are delayed, our revenues may be adversely affected.

     In the United States, the federal government, principally the FDA, and state and local government agencies regulate all pharmaceutical products, including existing products and those under development. Our pharmaceutical and biotechnology company partners may experience significant delays in expected product releases while attempting to obtain regulatory approval for products incorporating our technologies. If they are not successful, our revenues and profitability may decline. We cannot control, and our pharmaceutical and biotechnology company partners cannot control, the timing of regulatory approval for any of these products, or if approval is obtained at all.

     Applicants for FDA approval must often submit extensive clinical and pre-clinical data as well as information about product manufacturing processes and facilities and other supporting information to the FDA. Varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of a drug product. Changes in FDA approval policy during the development period, or changes in regulatory review for each submitted new product application, also may delay an approval or rejection of an application. The FDA has substantial discretion in the approval process and may disagree with our or our partners’ interpretations of such data and information which also could cause delays of an approval or rejection of an application. Even if the FDA approves a product, the approval may limit the uses or indications for which a product may be marketed, or may require further studies. The FDA can also withdraw product clearances and approvals for failure to comply with regulatory requirements or if problems follow initial marketing.

The FDA’s statutes, regulations or policies may change and additional government regulations or statutes may be enacted at any stage during product development or marketing, which may affect our ability to obtain or maintain regulatory approval of biological and other drugs or medical devices. Recent events have raised questions about the safety of marketed drugs and may result in new legislation by Congress and increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory approvals. This increased scrutiny by Congress and regulatory authorities may result in significant delays in obtaining regulatory approvals, as well as more stringent product labeling and post-marketing testing requirements. However, we cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad. Any delay in obtaining, or inability to obtain or maintain, applicable regulatory approvals could have a material negative impact on commercialization of the products of our pharmaceutical and biotechnology company partners, and post-approval restrictions or requirements could affect the commercial prospects of any product.

     Manufacturers of drugs also must comply with applicable current Good Manufacturing Practices (cGMP) requirements, both as a condition of approval and for continued authority to manufacture and distribute products. Our manufacturing facilities and those of our pharmaceutical and biotechnology company partners must pass a pre-approval inspection by the FDA, and will be subject to periodic inspection after that, all intended to ensure compliance with cGMP. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures, and we and our pharmaceutical and biotechnology company partners will need to ensure that all of our processes, methods, and equipment are compliant with the cGMP. We will be obligated to expend time, money, and effort in production, record keeping, and quality control to assure that the product meets applicable specifications and other requirements. If we or our pharmaceutical and biotechnology company partners cannot comply with these practices, the sale of our products or products developed by our partners that incorporate our technologies may be suspended. This would reduce our revenues and gross profits.

     If our products or products that incorporate our technologies are marketed in other jurisdictions, we and the partners with whom we are developing our technologies must obtain required regulatory approvals from foreign regulatory agencies and comply with extensive regulations regarding safety and quality. If approvals to market our products are delayed, if we fail to receive these approvals or if we lose previously received approvals, our revenues would be reduced. We may be required to incur significant costs in obtaining or maintaining foreign regulatory approvals.

We may face product liability claims related to participation in clinical trials or the use or misuse of our products or products that incorporate our technologies.

     The testing, manufacturing and marketing of our products or products that incorporate our drug delivery technologies may expose us to potential product liability and other claims resulting from their use. If any such claims against us are successful, we may be required to make significant compensation payments. Any indemnification that we have obtained, or may obtain, from contract research organizations or pharmaceutical and biotechnology companies conducting human clinical trials on our behalf may not protect us from product liability claims or from the costs of related litigation. Insurance coverage is expensive and difficult to obtain, and we may be unable to obtain coverage in the future on acceptable terms, if at all. Although, we currently maintain product liability and recall insurance in amounts we believe to be commercially reasonable, we cannot be certain that the coverage limits of our insurance policies or those of our strategic partners will be adequate. If we are unable to obtain sufficient insurance at an acceptable cost, a product liability claim or recall could adversely impact our financial condition. Similarly, any indemnification we have obtained, or may obtain, from pharmaceutical and biotechnology companies with whom we are developing our drug delivery technologies may not protect us from product liability claims from the consumers of those products or from the costs of related litigation. If we are subject to a product liability claim, our product liability insurance may not reimburse us, or be sufficient to reimburse us, for any expenses or losses we may suffer. A successful product liability claim against us, if not covered by, or if in excess of, our product liability insurance, may require us to make significant compensation payments. These payments would be reflected as expenses on our statement of operations and reduce our earnings.

Our commercial products are subject to continuing regulation and we may be subject to adverse consequences if we fail to comply with applicable regulations.

     We will continue to be subject to extensive regulatory requirements for our products and product candidates, even if they receive regulatory approval. These regulations are wide-ranging and govern, among other things:

	•		adverse drug experience and other reporting requirements;
	•		product promotion and marketing;
	•		product manufacturing, including cGMP compliance;
	•		record keeping;
	•		distribution of drug samples;
	•		updating safety and efficacy information;
	•		use of electronic records and signatures; and
	•		changes to product manufacturing or labeling.

     If we or our partners fail to comply with these laws and regulations, the FDA, or other regulatory organizations, may take actions that could significantly restrict or prohibit commercial distribution of products that incorporate our technologies. If the FDA determines that we are not complying with the law, it can, among other things:

	•		issue warning letters;
	•		impose fines;
	•		seize products or order recalls;
	•		issue injunctions to stop future sales of products;
	•		refuse to permit products to be imported into, or exported out of, the United States;
	•		suspend or limit our production;
	•		withdraw previously approved marketing applications; and
	•		initiate criminal prosecutions.

U.S. law or FDA policy could change and expose us to competition from “generic” or “follow-on” versions of our products, which may impact our market share and harm our business.

Under current U.S. law and FDA policy, generic versions of conventional chemical drug compounds, sometimes referred to as small molecule compounds, may be approved through an abbreviated approval process under the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act. There is no such process under current law for biological products approved under a biologic license application (BLA), such as growth factors, interferons and certain other proteins. The FDA generally has asserted that it lacks statutory authority to implement an abbreviated approval pathway for generic or “follow-on” biological products. Some have disagreed with this assessment, suggesting that the FDA has the necessary authority. In addition, there have been legislative proposals in Congress to explicitly grant the FDA such authority. If the law is changed or if the FDA otherwise concludes that it has authority to approve follow-on biologics, such an abbreviated approval process could adversely affect biological products that incorporate our technologies.

If our competitors develop and market drug delivery technologies or related products that are more effective than ours, or obtain regulatory approval and market such technology or products before we do, our commercial opportunity will be reduced or eliminated.

     Competition in the pharmaceutical and biotechnology industry is intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing drug delivery systems. Our Medusa^® technology competes with technologies from companies such as Alkermes, Inc., Enzon Pharmaceuticals, Inc., Human Genome Sciences, Inc., Nektar Therapeutics Inc., and SkyePharma, plc. Companies with oral drug delivery technology that can compete with our Micropump^® technology include Durect Corporation, Depomed, Inc., Biovail Corporation and Andrx Corporation. We also compete generally with other drug delivery, biotechnology and pharmaceutical and biotechnology companies that develop alternative drug delivery technologies or new drug research and testing.

     Many of these competitors have substantially greater financial, technological, manufacturing, marketing, managerial and research and development resources and experience than we do. Furthermore, acquisitions of competing drug delivery companies by large pharmaceutical companies could enhance our competitors’ resources. Accordingly, our competitors may succeed in developing competing technologies and products, obtaining regulatory approval and gaining market share for these products more rapidly than we do.

     Additionally, there could be new chemical entities that are being developed that, if successful, could compete against our technologies or products. Among the many experimental therapies being tested in the United States and in Europe, there may be some that we do not now know of that may compete with our drug delivery systems or products in the future. These chemical entities and new products may turn out to be safer or may work better than our technologies or products. Our collaborators could choose a competing drug delivery system to use with their drugs instead of one of our drug delivery systems.

If we cannot keep pace with the rapid technological change in our industry, we may lose business.

     Our success depends, in part, on maintaining a competitive position in the development of products and technologies in a rapidly evolving field. Major technological changes can happen quickly in the biotechnology and pharmaceutical industries. If we cannot maintain competitive products and technologies, our current and potential pharmaceutical and biotechnology company partners may choose to adopt the drug delivery technologies of our competitors. Our competitors may succeed in developing competing technologies or obtaining governmental approval for products before us, and the products of our competitors may gain market acceptance more rapidly than our products. Such rapid technological change, or the development by our competitors of technologically improved or different products, could render our drug delivery systems obsolete or noncompetitive.

Our products and technologies may not gain market acceptance.

     The competitive nature of our industry could adversely affect market acceptance of our products or the use of our drug delivery technologies. Even if we and our pharmaceutical and biotechnology company partners obtain the necessary regulatory approval to market our products and products that incorporate our technologies, our products, technologies and product candidates may not gain market acceptance among physicians, patients, healthcare payers and the medical community.

     The degree of market acceptance of any product, technology or product candidate will depend on a number of factors, including:

	•		the effectiveness of our marketing strategy;
	•		demonstration of the clinical efficacy and safety of the product or technology;
	•		no evidence of undesirable side effects which delay or extend trials;
	•		no regulatory delays or other regulatory actions;
	•		its cost-effectiveness;
	•		its potential advantage over alternative treatment methods; and
	•		the marketing and distribution support it receives.

     If any of our products or technologies fail to achieve market acceptance, our ability to generate revenue will be limited, which would have a material adverse effect on our business.

If we cannot adequately protect our technology and proprietary information, we may be unable to sustain a competitive advantage.

     Our success depends, in part, on our ability to obtain and enforce patents for our products, processes and technologies and to preserve our trade secrets and other proprietary information. If we cannot do so, our competitors may exploit our innovations and deprive us of the ability to realize revenues and profits from our developments.

     Any patent applications we may have made or may make relating to our potential products, processes and technologies may not result in patents being issued. Our current patents may not be exclusive, valid or enforceable. They may not protect us against competitors that challenge our patents, such as companies that submit drug marketing applications to the FDA that rely, at least in part, on safety and efficacy data from our products or our business partners’ products (e.g., abbreviated new drug applications), obtain patents that may have an adverse effect on our ability to conduct business or are able to circumvent our patents. Further, we may not have the necessary financial resources to enforce our patents.

     To protect our trade secrets and proprietary technologies and processes, we rely, in part, on confidentiality agreements with our employees, consultants and advisors. These agreements may not provide adequate protection for our trade secrets and other proprietary information in the event of any unauthorized use or disclosure, or if others lawfully develop the information.

Third parties have claimed, and may claim in the future, that our technologies, or the products in which they are used, infringe on their rights and we may incur significant costs resolving these claims.

     Third parties have claimed, and may claim in the future, that the manufacture, use or sale of our drug delivery technologies infringes on their patent rights. In response to such claims, we may have to seek licenses, defend infringement actions or challenge the validity of those patents in court. If we cannot obtain required licenses, are found liable for infringement or are not able to have these patents declared invalid, we may be liable for significant monetary damages, encounter significant delays in bringing products to market or be precluded from participating in the manufacture, use or sale of products or methods of drug delivery covered by the patents of others. We may not have identified, or be able to identify in the future, U.S. and foreign patents that pose a risk of potential infringement claims.

     Any claims that our products infringe or may infringe proprietary rights of third parties, with or without merit, could be time-consuming, result in costly litigation or divert the efforts of our technical and management personnel, any of which could disrupt our relationships with our partners and could significantly harm our operating results.

     We enter into collaborative agreements with pharmaceutical and biotechnology companies to apply our drug delivery technologies to drugs developed by others. Ultimately, we receive license revenues and product development fees, as well as revenues from the sale of products incorporating our technology and royalties. The drugs to which our drug delivery technologies are applied are generally the property of the pharmaceutical and biotechnology companies. Those drugs may be the subject of patents or patent applications and other forms of protection owned by the pharmaceutical and biotechnology companies or third parties. If those patents or other forms of protection expire, are challenged or become ineffective, sales of the drugs by the collaborating pharmaceutical and biotechnology company may be restricted or may cease.

If we or our collaborative partners are required to obtain licenses from third parties, our revenues and royalties on any commercialized products could be reduced.

     The development of some of our products may require the use of technology developed by third parties. The extent to which efforts by other researchers have resulted or will result in patents and the extent to which we or our collaborative partners are forced to obtain licenses from others, if available, on commercially reasonable terms is currently unknown. If we or our collaborative partners must obtain licenses from third parties, fees must be paid for such licenses. These fees would reduce the revenues and royalties we may receive on commercialized products that incorporate our technologies.

If we use biological and hazardous materials in a manner that causes injury, we may be liable for significant damages.

     Our research and development activities involve the controlled use of potentially harmful biological materials, hazardous materials and chemicals, and are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of those materials and specified waste products. We cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these materials. We currently maintain insurance coverage for environmental liabilities. If we fail to comply with environmental regulations, we could be subject to criminal sanctions and/or substantial liability for any damages that result, and any such liability could be significant.

Healthcare reform and restrictions on reimbursements may limit our financial returns.

     Our ability to successfully commercialize our products and technologies may depend in part on the extent to which the government health administration authorities, private health insurers and other third party payers will reimburse consumers for the cost of these products. Third party payers are increasingly challenging both the need for, and the price of, novel therapeutic drugs and uncertainty exists as to the reimbursement status of newly approved therapeutics. Adequate third party reimbursement may not be available for our drug products to enable us to maintain price levels sufficient to realize an appropriate return on our investments in research and product development, which could materially and adversely affect our ability to commercialize that particular drug. We cannot predict the effect that changes in the healthcare system, especially cost containment efforts, may have on our business. Any such changes may adversely affect our business.

Because we have a limited operating history, investors in our shares may have difficulty evaluating our prospects.

     We recorded the first commercial sales of products using one of our polymer technologies through our partner, Corning, in 1999. Our first commercial sales of a pharmaceutical compound incorporating our Micropump technology occurred in March, 2007 with the launch of Coreg CR. We have had no commercial sales to date of products incorporating our Medusa technology. Accordingly, we have only a limited operating history, which may make it difficult to evaluate our prospects. The difficulty investors may have in evaluating our prospects may cause volatile fluctuations, including decreases, in the market price of our shares as investors react to information about our prospects. Since 1995, we have generated revenues from product development fees and licensing arrangements and royalties. Our business and prospects, therefore, must be evaluated in light of the risks and uncertainties of a company with a limited operating history and, in particular, one in the pharmaceutical industry.

If we are not profitable in the future, the value of our shares may fall.

     We have accumulated aggregate net loss from inception of approximately $110.4 million through December 31, 2006. If we are unable to continue to earn a profit in future periods, the market price of our stock may fall. The costs for research and product development of our drug delivery technologies and general and administrative expenses have been the principal causes of our net losses in 2006, 2005, 2003, and 2001. Our ability to operate profitably depends upon a number of factors, many of which are beyond our direct control. These factors include:

	•		the demand for our technologies and products;
	•		the level of product and price competition;
	•		our ability to develop additional commercial applications for our products;
	•		our ability to control our costs;
	•		our ability to broaden our customer base;
	•		the effectiveness of our marketing strategy; and
	•		general economic conditions.

We may require additional financing, which may not be available on favorable terms or at all, and which may result in dilution of our shareholders’ equity interest.

     We may require additional financing to fund the development and possible acquisition of new drug delivery technologies and to increase our production capacity beyond what is currently anticipated. If we cannot obtain financing when needed, or obtain it on favorable terms, we may be required to curtail our plans to develop and possibly to acquire new drug delivery technologies or limit the expansion of our manufacturing capacity. We also may elect to pursue additional financing at any time to more aggressively pursue development of new drug delivery technologies and expand manufacturing capacity beyond that currently planned. Other factors that will affect future capital requirements and may require us to seek additional financing include:

	•		the development and acquisition of new products and technologies;
	•		the progress of our research and product development programs;
	•		results of our collaborative efforts with current and potential pharmaceutical and biotechnology company partners; and
	•		the timing of, and amounts received from, future product sales, product development fees and licensing revenue and royalties.

Our share price has been volatile and may continue to be volatile.

     The trading price of our shares has been, and is likely to continue to be, highly volatile. The market value of an investment in our shares may fall sharply at any time due to this volatility. In the year ended December 31, 2006, the closing sale price of our ADSs as reported on the NASDAQ National Market ranged from $16.70 to $34.88. In the year ended December 31, 2005, the closing sale price for our ADSs as reported on the NASDAQ National Market ranged from $12.25 to $21.37. The market prices for securities of drug delivery, biotechnology and pharmaceutical companies historically have been highly volatile. Factors that could adversely affect our share price include:

	•		fluctuations in our operating results;
	•		announcements of technological collaborations, innovations or new products by us or our competitors;
	•		governmental regulations;
	•		developments in patent or other proprietary rights owned by us or others;
	•		public concern as to the safety of drugs developed by us or others;
	•		the results of pre-clinical testing and clinical studies or trials by us or our competitors;
	•		litigation;
	•		decisions by our pharmaceutical and biotechnology company partners relating to the products incorporating our technologies;
	•		actions by the FDA in connection with submissions related to the products incorporating our technologies;
	•		the perception by the market of biotechnology and high technology companies generally; and
	•		general market conditions.

Our operating results may fluctuate, which may adversely affect our share price.

     Fluctuations in our operating results may lead to fluctuations, including declines, in our share price. Our operating results may fluctuate from period to period due to a variety of factors, including:

	•		demand by consumers for the products we produce;
	•		new product introductions;
	•		pharmaceutical and biotechnology company ordering patterns;
	•		the number of new collaborative agreements into which we enter;
	•		the number and timing of product development milestones that we achieve under collaborative agreements;
	•		the level of our development activity conducted for, and at the direction of, pharmaceutical and biotechnology companies under collaborative agreements; and
	•		the level of our spending on new drug delivery technology development and technology acquisition, and internal product development.

     Variations in the timing of our revenue and expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated earning shortfalls or losses.

          ITEM 4. Information on the Company

General Overview

     We are a biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications. Our Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, tastemasking and bioavailability enhancement. Our Trigger Lock™ technology is an adaptation of Micropump designed to prevent the misuse of medications subject to abuse; it also serves to avoid dose dumping in the presence of alcohol. Our Medusa nano-particulate technology is designed to deliver therapeutic proteins, peptides and small molecules. Our expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product that was launched by Corning in 1999.

     Our Micropump technology platform allows us to specifically tailor the pharmacokinetics of small molecule drugs best absorbed in the small intestine. Our lead product using Micropump technology is Coreg CR, which we developed with GlaxoSmithKline (GSK).

     We licensed Coreg CR to GSK in March, 2003. In September, 2004, we announced that GSK had initiated a Phase III trial for the formulation. In December, 2004, we announced that we had entered into a supply agreement with GSK for the production of Coreg CR microparticles at our plant in Pessac, France. The provisions of the agreement included payments such that Flamel did not incur cash outlays in connection with equipment to be used. The FDA has audited and approved our Pessac facility. This supply agreement was supplemented in July, 2006 when we announced that GSK had agreed to fund an expansion of the Pessac facility from two lines to three, in anticipation of expected increased demand for the product. The NDA for Coreg CR was submitted in December 2005 and the FDA approved the product for all requested indications (moderate to severe congestive heart failure; left ventricular dysfunction following myocardial infarction; and hypertension) on October 20^th, 2006. GSK launched the product in the U.S. in March, 2007.

     We currently have five major products or adaptations based on our Micropump technology which are not currently licensed to a third party: Trigger Lock, an adaptation of Micropump for the controlled release of active ingredients subject to abuse (such as narcotic analgesics); our Micropump-enabled formulation of omeprazole for control of gastric-reflux disease (GERD); Genvir, a controlled-release acyclovir for the treatment of genital herpes; Metformin XL, a controlled-release form of Metformin currently in development for use in the treatment of Type II diabetes; and co-amoxiclav, our Micropump-enabled formulation of the active ingredients in Augmentin^® for pediatric and geriatric use. A sixth product, Asacard^®, a controlled-release formulation of aspirin for the treatment of cardiovascular disease, was licensed in May of 2006 to RHEI Pharmaceuticals for the greater China territory.

     Our Medusa technology permits the long-acting controlled-release of proteins without the denaturation or other adverse effects on such proteins of certain other delivery systems. Our initial application of Medusais Basulin^®, a long-acting insulin for the treatment of diabetes.

     On August 27, 2003, we announced that we had entered into a license agreement with Bristol-Myers Squibb (BMS) for Basulin. The license agreement provided for an initial payment to us of $20 million and additional milestone payments that could have reached $145 million plus royalties on the sale of the product. BMS also would assume all costs of future clinical trials, development, registration and marketing of the product. On September 16, 2004, we received a letter notifying us of BMS’s intention to cancel the partnership. On December 15, 2004, ninety days after receipt of the cancellation letter, we re-obtained the rights to Basulin. On January 31, 2005, Flamel Technologies and BMS entered into a termination agreement, with respect to the former licensing agreement. Under the terms of the January 31, 2005 agreement, we received a cash payment of $5,850,000. We held discussions with potential pharmaceutical partners during the second half of 2005 regarding the potential licensing of the Basulin, which has been reformulated so as to provide lower viscosity. In 2006 we further re-formulated Basulin to extend its duration of action. We believe that the new formulation will effectively provide true once-daily dosing for all patients who require basal insulin, while maintaining the other advantages offered by Basulin compared to existing products on the market. These advantages include the fact that it is a recombinant human insulin with full bioactivity, both with respect to glucose control as well as Insulin’s role as a modulator of growth factors, especially vascular endothelial growth factor (VEGF). VEGF plays an essential role in maintaining vascular health .

     On December 8, 2004, we announced the initiation of a Phase I/II trial for Medusa-enabled long-acting interleukin-2 for the treatment of end-stage renal cancer. We reported the results of this Phase I/II trial at the May, 2006 annual meeting of the American Society of Clinical Oncologists (ASCO). The results showed 7 day duration of action and improved immunostimulation of CD-4, CD-8, and CD-25 as compared to Proleukin^®. We believe that these results represent the first time that interleukin-2 has been administered in a controlled release formulation.

     On December 17, 2004, we announced the initiation of a Phase I/II trial of Medusa-enabled long-acting interferon-alpha for the treatment of Hepatitis B and C. We announced the results of this study at the XII Annual International Symposium on Viral Hepatitis and Liver Disease in July, 2006. The results showed strong bioactivity and reduced side-effects as compared to Viraferon^®. Applications of Medusa to other therapeutic proteins, including beta-interferon and human growth hormone are in an advanced stage of pre-clinical development.

     We have had a long-standing collaborative relationship with Corning to develop advanced polymeric photochromic materials for eyeglass lenses. We have enjoyed seven years of royalties as a result of sales of this product. This is also the first product containing our technology to have been commercialized.

     The Company was incorporated as a societe anonyme, a form of corporation under the laws of the Republic of France in August of 1990, and its shares were quoted on the NASDAQ National Market in 1996. Flamel’s principal place of business is located at Parc Club du Moulin a Vent, 33, avenue du Docteur Georges Levy, 69693 Venissieux Cedex France, telephone number 011 33 (4) 72 78 34 34. Flamel’s agent in the United States is Flamel Technologies, Inc., 1825 K Street, Suite 1210, N.W., Washington, DC 20006. A list of the company’s significant subsidiaries can be found in Exhibit 8.1.

The Need for Novel Delivery Systems

     Our polymer delivery systems are currently focused on the controlled release of therapeutic proteins and the oral administration of pharmaceutical drugs, primarily those that are best absorbed in the small intestine. The pharmaceutical industry utilizes drug delivery technologies as a tool to improve existing products as well as to overcome certain problems encountered in the development of new products. Drug delivery technologies enable pharmaceutical companies to improve the safety and efficacy profiles of innovative new therapeutic compounds, to improve patient compliance and acceptance of existing drugs, to expand therapeutic indications of an existing drug, and to gain competitive advantages for drugs facing patent expirations. It is estimated that pharmaceutical product sales utilizing advanced drug delivery technologies amounted to approximately $83 billion worldwide in 2006.

Business Strategy

     We aim to build on our core strength as a science based, market focused innovator of controlled release drug delivery systems. The key elements of our strategy that will enable us to build upon our strengths are as follows:

	•		maximize the potential of our existing drug delivery systems;
	•		develop or acquire additional drug delivery technologies;
	•		identify additional compounds for unmet medical needs;
	•		develop new formulations of proprietary compounds that we receive from additional partners; and
	•		leverage capabilities of pharmaceutical partners for clinical development and commercialization.

     For the reasons set forth below in this Item 4, we believe that we have a competitive advantage in developing controlled-release formulations of proteins, peptides and small molecules that improve dosing, compliance and efficacy. We remain committed to focusing on our strengths. We will continue to partner our proprietary formulations with pharmaceutical companies with the clinical, regulatory and marketing resources to secure regulatory approval and to commercialize these pharmaceuticals successfully.

     Under our partner agreements, our pharmaceutical company partners typically assume responsibility for all clinical, regulatory and marketing costs and make payments to us at the time the agreement is signed and upon the achievement of significant technical, clinical and regulatory milestones. We also typically are entitled to receive ongoing royalty payments on the sales of pharmaceuticals that incorporate our technologies.

Micropump^®: Delivery System for the Oral Administration of Drugs

     Our first drug delivery platform, Micropump, is an oral multiparticulate technology with applications in sustained release, tastemasking and bioavailability enhancement.

     Micropump provides a method of encapsulating microscopic-sized particles or granulates of a pharmaceutical compound with carefully selected polymers designed to achieve a desired pharmacokinetic profile. These microparticles have dimensions that are intended to control the absorption rate of the drug. Each microparticle acts as an independent drug delivery vehicle that slowly releases particles, since they can be ‘programmed’ for each drug and each therapeutic indication by modifying the thickness and composition of the polymer coatings and the excipients encapsulated with the drug.

     We believe that Micropump particles, which measure approximately 200 to 500 microns in diameter, can provide benefits in controlled release and in the taste-masking of bad tasting active materials. The latter use is particularly important where the microparticles are dosed in sachet or liquid suspension, or as rapidly dissolving tablets. In addition, we believe that our Micropump technology can facilitate improvements in the bioavailability of certain drugs whose low solubility profile restricts both the rate and extent of absorption. We have demonstrated that the incorporation of certain hydrophilic excipients into the Micropump particles leads to marked improvements in drug stability, which may, in turn, lead to enhancement of bioavailability. We are currently pursuing this application for the Micropump technology. Many new and effective drug compounds demonstrate poor stability characteristics, which can hamper the ability of these compounds to be successfully developed and commercialized. We believe that a drug delivery technology which has application in stabilizing such compounds would have significant value. The reformulation of existing compounds to incorporate such advantages would potentially extend the patent life of such compounds, which in itself would provide a major benefit to our partners.

     Micropump technology has several other key attributes, including a high loading ratio of active ingredient to its polymer coating, allowing for conventional size tablets or capsules. This is important for some products, such as acyclovir, where large daily doses are required. The large number of microparticles contained in a tablet or capsule also enhances safety by avoiding the problem of dose-dumping (releasing all of the dose at one time/one place). Dose-dumping can give rise to side effects such as ulceration. In addition, changes in pH levels within a patient’s body have been shown not to affect the Micropump particle coating, unless so designed. This coating uses a class of material approved for pharmaceutical use by the FDA, which may accelerate testing and approval.

     Our Trigger-Lock™ technology is an adaptation of the Micropump platform designed to prevent misuse of drugs subject to abuse, such as narcotic analgesics like Oxycontin. Such drugs are designed as controlled release formulations for the treatment of moderate to severe pain. When abused by recreational drug users, the controlled release mechanism is circumvented in such a way as to achieve the immediate release of the active ingredient. It is a significant medical and societal problem which has garnered a high level of attention from local, state, and federal officials in the U.S., as well as public health officers in the rest of the world. Because of their size, Micropump particles cannot be crushed, meaning that the platform is resistant to the most common method of misuse. Further modifications to the platform have been tailored to prevent other less publicized methods of foiling currently-marketed controlled release systems. We believe that our Trigger-Lock technology is at least as good as competing technologies with respect to the prevention of potential abuse while also providing substantially better pharmacokinetic to patients when taken as directed. This combination of safety and pharmacokinetic efficacy could potentially enable us to create a best in class platform for the controlled release of drugs subject to abuse.

     Moreover, we believe that there is potential wide applicability of the Trigger Lock technology with respect to the prevention of alcohol-related dose-dumping in the presence of alcohol. Recently, greater attention has been paid to the problem of controlled release formulations that are compromised when taken in conjunction with alcohol. This scrutiny extends beyond controlled substances that are particularly subject to abuse; it also concerns those drugs that are titrated until a patient begins to feel side-effects, such as cardiovascular drugs and anti-depressants. The expertise that we have gained in the development of our Trigger Lock platform has benefits that extend beyond controlled substances and are applicable to the entire Micropump platform.

     Products Based on the Micropump^® Technology

     We believe that our Micropump system is most appropriate for delivery of therapeutic compounds for which the small intestine is the optimal site of absorption and where the extension of mean plasma concentration time is important. Our first approved product using the Micropump platform is Coreg CR, which we have developed with GSK.

     1. Coreg CR

     Beginning in 2003, we have worked with GSK to develop Coreg CR, an extended release formulation of carvedilol phosphate. Coreg CR is a next generation formulation of Coreg, a beta blocker that is considered the standard of care for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. Under the terms of our license agreement with GSK, signed in 2003, we will receive milestones totaling $25 million, of which $17 million have been received as of December 31, 2006, as well as royalties on the sale of the product. GSK also agreed to pay all of the costs of research and development for the product. Under the supply agreement with GSK that we signed in December, 2004, we expanded our capacity for the production of microparticles at our plant in Pessac, France at no cost to us. In July, 2006, we announced that GSK had agreed to sponsor the expansion of our plant in Pessac, from two lines to three, in anticipation of increased demand for the product. Coreg CR was approved by the FDA on October 20, 2006 for use in the treatment of moderate to severe congestive heart failure; left ventricular dysfunction following myocardial infarction; and hypertension.

     The Market for Beta Blockers.

     Beta blockers are indicated for the treatment of Congestive Heart Failure (CHF) as well as to treat hypertension. Additionally, Coreg and Coreg CR are indicated for the treatment of left ventricular dysfunction following myocardial infarction. For some years, Coreg has been the market leader in the treatment of CHF; it is the only beta blocker approved for the treatment of moderate to severe CHF. Coreg has attained this leadership position despite the fact that it was not available in a once-daily formulation, unlike the rest of the beta blocker class. In general, many physicians prefer once-daily formulations for their patients due to the compliance advantages that they offer. Compliance is especially important when treating CHF patients, many of whom are elderly and are required to take a substantial amount of medications on a daily basis. Non-compliance is one of the leading causes of heart failure hospitalization.

     Earlier generations of beta blockers have not been widely used in the treatment of hypertension because of perceived drawbacks. The greatest of these drawbacks, perhaps, was the fact that other beta blockers, with the exception of Coreg and Coreg CR, have been associated with increased glycemia levels in Type II diabetic patients. Many hypertension patients in the U.S. suffer from Type II diabetes; in fact there are over 13 million Type II diabetic hypertensives in the U.S. According to the Centers for Disease Control, many more hypertensive patients suffer from what is referred to as metabolic syndrome, meaning that they have a combination of factors that affect their health in an interrelated fashion; these patients are considered to be at-risk for Type II diabetes. They may even have what is known as pre-diabetes, meaning that their blood sugar levels are above average but do not yet reflect the level loss of insulin sensitivity that defines Type II diabetes.

     Type II diabetics who suffer from hypertension are defined by the American Diabetes Association as suffering from complicated hypertension, meaning that they are recommended to reduce their blood pressure to a level of 130/80 (as opposed to 140/85 for essential hypertension). Sixty-five percent of those suffering from Type II diabetes, it is estimated, will require two or more anti-hypertensive agents.

     The immediate release formulation of Coreg (carvedilol) generated revenues of $1.44 billion in 2006. Sales of Coreg have grown over 30% annually for the past three years, driven in large part by increased market share garnered in the treatment of congestive heart failure and related indications. Carvedilol is a non-selective antagonist of Beta 1, Beta 2 andrenergic receptors and a selective antagonist of Alpha 1 andrenergic receptors. It has been demonstrated to have notable anti-inflammatory properties, in distinction to other beta blockers. Research further suggests that carvedilol possesses significant anti-oxidative effects, which are beneficial to vascular health. Lastly, and perhaps most significantly, Coreg is the only approved beta blocker shown not to raise glycemia levels in Type II diabetic patients; in fact, they may serve to raise insulin sensitivity in these patients.

     2. Lansoprazole extended release

     Beginning in 2004, we worked with TAP Pharmaceutical Products, Inc. (TAP), the joint venture between Abbott Laboratories, Inc. and Takeda Pharmaceutical Company, Ltd., to develop an extended release formulation of lansoprazole, which is marketed in the U.S. under the brand name Prevacid^®. Prevacid was the third largest selling drug in the United States in 2006 with sales of $3.3 billion. Prevacid is a proton pump inhibitor (PPI) that works by helping to prevent the creation of acid in the stomach. Stomach acid may cause heartburn and can lead to a condition known as acid-reflux disease, caused when stomach acid backs up into the esophagus. Under the terms of the license agreement, TAP was obligated to pay all costs of development, testing, regulatory approval and marketing of the new formulation. Flamel also had the potential to earn more than $100 million of milestones and to receive significant royalties on sales of the product. On September 2, 2005, TAP delivered a letter notifying us of their decision to terminate the partnership. The decision followed Takeda Pharmaceuticals announcement that TAP would conduct Phase III clinical trials on Takeda’s enantiomer of lansoprazole. The termination became effective in December 2005.

     The Market for Proton Pump Inhibitors

     We estimate global sales of proton pump inhibitors to have been $23 billion in 2006. As a class, only lipid lowering agents had greater sales. The demand for proton pump inhibitors stems both from the prevalence of patients who suffer from acid reflux and increased awareness about the disease. Seven percent of Americans suffer the symptoms of acid reflux disease on a daily basis and an additional fourteen percent suffer from the disease twice a week. The potential long-term complications of acid-reflux disease, if left unchecked, include erosive esophagitis and even esophageal cancer.

     Using Micropump, we have demonstrated that we can increase both the efficacy and convenience of lansoprazole to such a degree that the new formulation demonstrates clear superiority in comparison to the best in class marketed products. Furthermore, we have confirmed these results with respect to a Micropump-enabled formulation of omeprazole (the active ingredient in Prilosec^®, which is off-patent) in comparison to Nexium^®. According to Astra Zeneca, Nexium sales totaled $4.6 billion in 2006.

     3. Genvir ™: Controlled-release Oral Acyclovir

     We have applied our Micropump technology to develop a controlled-release formulation of acyclovir for the treatment of genital herpes.

     The Market for Anti-Herpes Drugs

     We estimate the worldwide market for the treatment of herpes infections to have been approximately $2.2 billion in 2006. Acyclovir, including multiple generic formulations and GlaxoSmithKline’s Zovirax^®, as well as prodrug formulations of acyclovir, are currently the leading drugs for the treatment of herpes infections. There are two relatively expensive, second-generation prodrugs of acyclovir. The most successful of the two is GlaxoSmithKline’s Valtrex, which had sales of approximately $1.6 billion in 2006. These second-generation drugs address a principal weakness of acyclovir: its arduous dosing regimens. For the acute genital herpes and zoster indications, acyclovir needs to be taken five times per day; for chronic genital herpes indications, acyclovir needs to be taken twice per day. These second generation drugs have reduced the dosing schedule to three times per day for zoster, two times per day for acute genital herpes and one to two times per day for chronic genital herpes.

     Controlled-Release Acyclovir for Acute Genital Herpes

     Genvir is an oral drug also offering a twice per day dosing regime for the treatment of acute genital herpes. Using Micropump, we have overcome the obstacles presented by the particular absorption characteristics of acyclovir to improve its pharmacokinetic profile and develop an effective, controlled-release formulation of the drug. Genvir, with a dosing schedule equivalent to Valtrex, is positioned as a second-generation treatment for acute genital herpes and as an alternative to the acyclovir prodrugs.

     As shown in its European phase III study, Genvir taken twice a day provides the same effective treatment for acute genital herpes as Zovirax (brand-name acyclovir) taken five times a day. The double-blind phase III clinical study of Genvir was conducted in France and Germany with 596 patients enrolled, 423 of whom were treated for an acute attack of genital herpes. In this study, Genvir 600mg taken twice a day was demonstrated to be therapeutically equivalent to Zovirax 200mg taken five times a day. The principal endpoint in the study was the percentage of patients with healed herpes lesions on the fifth day. The study concluded that 53.6% of Genvir-treated patients had healed lesions as compared to 45.7% of Zovirax-treated patients. Additionally, the occurrence of new herpes lesions in the Genvir-treated patients was less than in the Zovirax-treated patients. The safety profiles of both drugs were excellent and similar.

     4. Asacard^®162.5mg: Controlled-Release Cardiovascular Aspirin

     Asacard is a controlled release formulation of aspirin, designed to provide effective and safe therapy for cardiovascular treatment. Aspirin is a highly effective prophylactic treatment that promotes cardiovascular health. For many users, however, aspirin causes gastro-intestinal damage because it inhibits the Cox-1 enzyme. Asacard’s advantage is that the release of aspirin is controlled such that substantially all of the aspirin is metabolized in the liver before reaching the circulatory system. This allows the aspirin to maintain all of its benefits while drastically reducing the potential gastro-intestinal side-effects associated with Cox-1 inhibition.

     In May of 2006, we announced that we had entered into a licensing contract with RHEI Pharmaceuticals, Inc. The agreement grants RHEI the exclusive right to market Asacard in the Greater China region (including China, Taiwan, Hong Kong and Macau). Flamel will manufacture commercial supply of the product at its facilities in Pessac, France.

     Other Products Based on Micropump Technology

     From time to time we have conducted Micropump feasibility studies on other proprietary therapeutic compounds under limited, confidential agreements with the pharmaceutical companies owning the rights to these compounds. Such contracts provide us with the possibility for expanded relationships. Moreover, these relationships are invaluable insofar as our potential partners are often able to identify opportunities for the Micropump platform from their internal pipeline, opportunities which we would not otherwise know.

Medusa^®: Delivery System for Therapeutic Proteins and Peptides

     Therapeutic agents based on biological proteins and peptides are becoming increasingly important. According to our estimates, the worldwide market for currently approved therapeutic proteins is over $67 billion annually; the growth of this market is expected to be significant as new products are commercialized. In developing these products, a principal challenge is finding a suitable delivery system that can transport the protein or peptide to its site of action, release it at the optimal therapeutic rate, and protect it from being unduly degraded without denaturing it (i.e., causing a structural change that results in a loss of the properties that are linked to its precise structure).

     The scientific challenges to developing such a controlled-release process for protein-based drugs are significant. For a polymer-based delivery system, these constraints require a polymer that:

	•		can be metabolized by the human body into harmless substances;
	•		is compatible with the protein or peptide;
	•		keeps the structure of the protein intact;
	•		protects the therapeutic agent during transit and delivery; and
	•		has the required release properties once delivered.

     Responding to these scientific challenges and to what we believe is a significant market opportunity, we have developed Medusa, a delivery system designed to deliver proteins and peptides in a controlled manner without denaturation. Our approach utilizes a novel nano-particulate system, combined with a polyaminoacid biopolymer, that meets the above conditions. We have developed a protein-like polyaminoacid composed of only one or two different amino acids. We have tailored this polyaminoacid polymer to form nano-scaled particles spontaneously in water that entrap proteins without the use of solvents or any surfactants. This ‘self-assembly’ process is critical in avoiding the denaturing of the proteins. The “ubiquitous” polymer is potentially applicable across substantially all therapeutic proteins and peptides. One advantage of this approach is that we do not anticipate the necessity to conduct individual toxicity and carcinogenicity tests for each product that we develop using the technology. That is because the bond created in the self-assembly process is a physical bond and not a chemical one. We have shown in animal studies that this polyaminoacid polymer is neither immunogenic nor reactogenic. Nevertheless, further testing is necessary in each application of Medusa to a drug, including Basulin, to demonstrate that each product does not pose a potential risk for human subjects.

     1. Basulin^®: Long-acting Basal Insulin Formulation

     Our first application of our proprietary Medusa technology is a depot delivery formulation of insulin targeted to meet the long-acting, ‘basal’ insulin requirements of diabetic patients.

     Insulin Market

     Insulin serves to regulate the glucose level in the blood. In a non-diabetic person, the body produces insulin in large quantities after each meal to reduce the resulting high glucose level. The body also produces a small quantity of insulin every 15 minutes to ensure that a basal level of insulin is maintained throughout the day. To maintain similar control over their glucose levels, diabetics who need insulin also require two different types: a fast-acting insulin to be taken at meal times, and a long-acting insulin to maintain a constant minimum level of needed insulin, particularly throughout the night when patients do not inject insulin.

     The worldwide market for insulin is estimated by the Company to have been approximately $ 8.9 billion in 2006. Of this total, long-acting basal insulin is estimated by us to constitute nearly $4.6 billion in annual sales. In Type I diabetics (those with Insulin Dependent Diabetes Mellitus), basal insulin is projected to represent 40% of their required treatment. Type II diabetics (those with Non-Insulin Dependent Diabetes Mellitus) significantly out-number Type I diabetics and often require only basal insulin. Our Basulin is designed to address the long-acting basal insulin requirements of both of these groups.

     The Development of Basulin

     Using our Medusa delivery system, we have been able to form nano-particles of human insulin with our proprietary polyaminoacid polymer to produce a long-acting, injectable insulin formulation, Basulin.

     In diabetics, large variations in blood glucose levels over time can lead to serious, long-term complications including vision impairment, foot ulcerations and kidney failure. Minimizing the peaks and valleys of a diabetic’s blood glucose level is thought to prevent such serious long-term complications. Theoretically, an insulin release profile with minimal peak and trough differences should minimize a diabetic’s hypoglycemia and hyperglycemia (low and elevated blood glucose levels) episodes, particularly during the first hours after insulin injections and during the sleeping hours. Basulin has been shown to provide a controlled-release of fully human insulin over 24 hours with good bioavailablity and excellent local tolerance. Among Basulin’s potential advantages is the fact that it is a recombinant human insulin with full bioactivity, both with respect to glucose control as well as insulin’s role as a modulator of growth factors, especially VEGF. VEGF plays an essential role in maintaining vascular health.

     On August 27, 2003, we announced that we had entered into a license agreement with Bristol-Myers Squibb for Basulin. The license agreement provided for an initial payment to us of $20 million and additional milestone payments that could have reached $145 million plus royalties on the sale of the product. Bristol-Myers Squibb also would assume all costs of future clinical trials, development, registration and marketing of the product. On September 16, 2004, we received a letter notifying us of Bristol-Myers Squibb’s intention to cancel the partnership. On December 15, 2004, ninety days after receipt of the cancellation letter, we re-acquired the rights to Basulin. On January 31, 2005, Flamel Technologies and BMS entered into a termination agreement, with respect to the former licensing agreement. Our work on Basulin has continued and in 2006 we made substantial strides towards an improved formulation which, if proven in clinical tests, we believe may provide 24 hour coverage to 100% of patients who require basal insulin, as opposed to the current standard of care, which provides approximately 65% to 75% of patients with 24 hour coverage. Further, we believe that this prolonged and even controlled release profile will provide better glucose control for patients with less risk of hypo-glycemic events. We plan to conduct a Phase I trial of our newest formulation of Basulin to establish its pharmacokinetic properties and efficacy in controlling blood glucose levels, using the clamp technique.

     2. Interferon

     We believe that the Medusa delivery system has the potential to improve formulations of other important biological drugs. In December 2004, we initiated a Phase I/II clinical trial of Medusa enabled long-acting interferon-alpha (IFN-alpha XL). We presented the data from this study at the XII Annual International Symposium on Viral Hepatitis and Liver Disease in July, 2006. The results strengthen our belief that the therapeutic profile of interferon alpha, particularly in the treatment of Hepatitis C and cancer, can be improved if its peak concentration in the blood (Cmax) is reduced. One key advantage of the Medusa-enabled formulation of interferon-alpha is its improved safety profile. One administration of 27 million international units of Flamel’s Medusa IFN-XL resulted in lesser side effects in patients than those who received three doses of three million international units over the course of one week. IFN-alpha XL allows for the possibility of lesser side-effects at constant dosing, the potential for administering higher doses for greater efficacy, or some combination of the two.

     We estimate the worldwide market for interferon drugs to have been $6.8 billion in 2006 and we expect this market to grow in the future as researchers identify additional indications that may be treated effectively using interferon drugs, as such proposed treatments gain approval and as new suppliers emerge. In 2006, we estimate that interferon alpha formulations accounted for approximately 35% of the worldwide market for interferons.

     3. Interleukin

     In December 2004, we initiated a Phase I/II clinical trial of Medusa-enabled long-acting interleukin-2 (IL-2 XL) for the treatment of renal cancer. We believe that the use of IL-2 as a treatment for renal cancer as well as in other indications has been limited due to its extreme toxicity. Pre-clinical studies of our long-acting interleukin-2 versus Proleukin^® in monkeys showed an increase in the duration of action of the drug, with a lower blood concentration of drug after injection (Cmax). Flamel’s formulation resulted in measurable increases in levels of lymphocyte CD4 and CD8, and the soluble fraction of CD25 in the monkeys studied, which are considered surrogate markers for stimulation of the body’s immune system. These results were confirmed in the Phase I/II clinical trial, the results of which we presented at the 2006 general meeting of the American Society for Clinical Oncology (ASCO). In addition to its application for advanced kidney cancer, IL-2 XL could be used in further oncology indications where immune response plays a significant role because of its potentially improved safety profile. IL-2 XL could also become an important adjuvant for vaccines as well as in the treatment of HIV. Specifically, IL-2 XL could be used to allow patients who have undertaken combination therapy to suspend such therapy, to reduce the load on the liver. Further, with respect to patients with severely compromised immune systems, as evidenced by suppressed CD-4 counts, it is possible that IL-2 could serve to greatly boost their immune system.

     Other Products Based on the Medusa^® Technology

     In a further effort to leverage our knowledge of Basulin and the Medusa technology, we have sought and received French government funding for research activity related to additional applications of our Medusa technology. These are in the feasibility testing phase.

Photochromic Materials

     Our expertise in polymer science has led to a long-term collaborative relationship with Corning. Under a contract research arrangement that has existed since 1994, we have worked with Corning to produce two generations of material for photochromic lenses. The research and development activities ended in 2003.

     Photochromic lenses automatically darken in the presence of sunlight and then revert to clear when indoors. These eyeglass lenses, which are based on mineral material, have been available for over 20 years, and Corning has been the dominant worldwide supplier of these lenses since their introduction. However, as eyeglass lenses have been increasingly made with plastic materials, there is an increasing demand for photochromic lenses based on polymer (plastic) materials. We believe that Corning, which is building an existing franchise and business expertise in the eyeglass lens market, is well positioned to compete effectively in the worldwide market for polymer-based photochromic lens material.

     During 1999, Corning launched SunSensor™, a new, competitive photochromic eyeglass lens product containing our technology. We began receiving royalties on the sales of this product late in 1999. The amount of future royalties related to this and other potential products resulting from this collaboration is dependent on Corning’s marketing success.

     Under the terms of our current agreement with Corning, we continue to receive royalties on sales of all products that contain intellectual property developed by the collaboration. See ‘— Strategic Alliances — Corning: Photochromic Materials.’

Strategic Alliances

     In order to develop and apply our technologies efficiently and effectively commercialize the resulting products, we have entered into, and intend to continue to enter into, collaborative arrangements with large biotechnology and pharmaceutical company partners. Such arrangements typically provide funding for development work and access to target compounds and related know-how and, ultimately, provide distribution capabilities for any resulting products. Such arrangements generally include termination provisions in the event either party decides that, for strategic or other reasons, it does not wish to pursue the alliance. Our existing agreements are as follows:

     GlaxoSmithKline

     On March 28, 2003, we announced that we licensed our Micropump technology to GlaxoSmithKline for the development of Coreg CR. We announced in September of 2004 that GlaxoSmithKline had begun a Phase III clinical trial of the product. We received a $2 million milestone payment as a consequence of the Phase III trial initiation. In December of 2004, we announced that we signed an agreement whereby Flamel will supply GlaxoSmithKline with commercial supplies of the drug. The provisions of the agreement include payments such that we will not have cash outlays in connection with equipment to be used. On October 26, 2005, we announced that GSK had determined that successful Phase III results had been obtained on this product. The determination triggered a $2 million milestone payment. On December 21, 2005, we announced that GSK had submitted a New Drug Application to the FDA for the product. In February, 2006, we received a $2 million milestone payment following the submission of a NDA for Coreg CR. This supply agreement was supplemented in July, 2006 when we announced that GSK had agreed to fund an expansion of the Pessac facility from two lines to three, in anticipation of expected increased demand for the product. Coreg CR received an approval letter from the FDA on October 20, 2006, triggering the receipt of a $3 million milestone payment. In March, 2007, GSK launched Coreg CR in the U.S. and we received a further $1 million milestone.

     TAP

     On September 16, 2004, we announced that we had entered into a licensing agreement with TAP Pharmaceuticals, Ltd. for an extended release formulation of lansoprazole, the active ingredient in Prevacid^®. The license agreement provides for milestone payments of up to $100 million as well as royalties on the sale of the product TAP Pharmaceuticals, Ltd. also assumed all costs of future clinical trials, development, and marketing of the product. On September 5, 2005, we announced that we had received a letter from TAP Pharmaceuticals, Ltd. notifying us of their intent to terminate the agreement. The termination became effective in December 2005.

     Bristol-Myers Squibb

     On August 27, 2003, we announced that we had entered into a licensing agreement with Bristol-Myers Squibb for Basulin. The license agreement provided for an initial payment to us of $20 million, and additional milestone payments that could have reached $145 million plus royalties on the sale of the product. In March of 2004, we announced that we had received a $5 million milestone payment for the delivery of the phase II-b trial batch. On September 16, 2004, we announced that we had received a letter of termination from Bristol-Myers Squibb. On December 15, 2004, ninety days after receipt of the cancellation letter, we re-acquired the rights to Basulin. On January 31, 2005, Flamel Technologies and BMS entered into a termination agreement, with respect to the former licensing agreement.

     Biovail

     On April 9, 2003, we announced that we entered into an agreement with Biovail to license our Genvir product for the United States and Canada. We retained the rights to the product in the rest of the world. Under the agreement, Biovail was responsible for all development, clinical and regulatory costs associated with the filing and approval of the product in the U.S. and Canada. Biovail was also responsible for all expenses associated with the marketing, sales, advertising and promotion of the product in these markets. On March 3, 2005, Flamel sent a termination letter to Biovail. The agreement was terminated effective upon receipt of the letter by Biovail.

     Servier

     On January 11, 2002, we announced that we entered into a licensing agreement with Servier for application of our Micropump technology to an ACE inhibitor that is proprietary to Servier. We received $3 million upon signing of the agreement and total payments of over $10 million during 2002. In 2003, we received an additional $1,283,000 in research and development revenues and we recognized one milestone payment of $484,000 as licensing revenue.

     Merck & Co.

     Effective September 30, 2001, we entered into a licensing agreement with Merck for an undisclosed class of products.

     Corning: Photochromic Materials

     Corning France, on its own behalf and representing Corning Incorporated and Corning Europe Inc., entered into an agreement with us in March 1994 for the co-development of proprietary, polymer-based photochromic eyeglass lens material to be sold by Corning to manufacturers of ophthalmic lenses worldwide. Under this agreement, from March 1994 to February 1998, Corning financed our related research and development costs. This agreement also entitled us to royalty payments based on Corning’s net sales, if any, of ophthalmic products that contained materials developed in conjunction with us.

     On December 31, 1998, we entered into a new, long-term collaboration and development agreement with Corning S.A. and Corning Incorporated that expanded the scope and applicability of the earlier agreement. Under this new agreement, Corning owns all intellectual property developed with us. However, under specified conditions, we will have the right to use technology developed under the collaboration for applications other than photochromic eyeglass lenses or sunglass lenses. While we previously were entitled to receive royalties on the sales of all products containing intellectual property resulting from the collaboration, the new agreement provides for an increase in royalties on sales of certain products.

     In 1999, Corning launched its first photochromic plastic eyeglass lens product developed in collaboration with us, and we began receiving quarterly royalty payments under this agreement. The year 2006 was the seventh full year of royalties for us for this product and we received approximately $674,000 in royalties.

Manufacturing

     On December 31, 1996, the Company acquired a 50,000-square foot pharmaceutical production facility located in Pessac, France from SmithKline. See ‘Item 4. Key Information — Description of Property.’ As part of the acquisition, Flamel employed forty-two experienced plant personnel and entered into a three-year toll manufacturing agreement with SmithKline for cimetidine formulations. The Company has consistently met SmithKline’s production requirements. The agreement was extended through the year 2005.

     Up until 2005, activities at this facility included contract manufacturing for GlaxoSmithKline and other major pharmaceutical companies, process and scale-up activities and the production of clinical batches for our own products, as well as support analytical services for SmithKline and other pharmaceutical laboratories. As our products are commercialized, we expect that this facility will provide necessary quantities of some portion of our products other than Coreg CR.

     In 2004, we built a new facility of 16,000 square feet for a total purchase price of $10.3 million. This new building included 8,600 square feet for the Medusa technology with a new cGMP pilot plant, extended synthesis capacity and increased capacity to manufacture qualification and phase III lots at 10% of the commercial batch size. This will support the production of polymer to meet the needs from projects such as Basulin, interferon-alpha, and interleukin-2. A further building comprising 2,900 square feet houses utilities and a warehouse.

     In 2005, we expanded our facilities in preparation for the manufacture of Coreg CR microparticles for GlaxoSmithKline as well as other Micropump-enabled formulations. The new facility comprises 6,800 square feet and includes the 4,600 remaining square feet from the 2004 expansion. The new Micropump facility was constructed at a cost of $8.2 million. See pages F-13 of our consolidated financial statements.

     The Pessac facility provides the Company with the capability to manufacture its pharmaceutical products. The Company believes that the facility and its operations are in substantial compliance with current ‘Good Manufacturing Practice’ (cGMP) requirements, and the facility is approved by U.S. and European drug agencies for production of certain pharmaceutical products, including commercial quantities of the Company’s microencapsulated drugs. Such approval qualifies the Company to manufacture certain approved pharmaceutical products for sale in most countries in Europe and the U.S.

     In the past, in addition to production activities related to its core businesses, Flamel was able to build on its capabilities and experience with GlaxoSmithKline and other pharmaceutical customers to engage in toll manufacturing for pharmaceutical partners. With its experienced workforce and cGMP operations, the Company provided clinical batch manufacturing, process scale-up services and toll manufacturing of solid dosage forms, and also provided analytical services for contract customers up until the last quarter of 2005. Our production site at Pessac is currently in full-scale production of Coreg CR microparticles.

Patents and Proprietary Technology

     Patents and other proprietary rights are important to our business. As a matter of policy we seek patent protection of our inventions and trademarks and also to rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. Generally, we first file a patent application covering an invention in France and then file counterpart patent applications for the invention within one year in other countries.

     Since inception, we have been granted 275 patents. Among others, these include patents that relate to microencapsulated aspirin ASACARD, microencapsulated active principle MICROPUMP, methods of producing polyaminoacids for use in delivering proteins and peptides, and nanoparticles of polyaminoacids for delivering proteins and peptides MEDUSA, BASULIN, as well as made of the nanoparticles. In the case of the French patents, we currently have counterpart patents or patent application pending in other European nations, Japan and the United States. We have several additional patent applications pending in France, other European nations, Japan, the United States and some additional countries.

     Throughout, 2006, we filed for 6 new patent applications with the French Patent Office and corresponding US provisional applications. We have also filed 15 Patent Cooperation Treaty (PCT) extensions of cases first filed in 2005 and corresponding direct US non provisional patent applications.

     We can offer no assurance that any patents issued to us will provide us with competitive advantages or will not be infringed, challenged, invalidated or circumvented by others, or that the patents or proprietary rights of others will not have an adverse effect on our ability to do business.

     There can be no assurance that we will be granted patents in respect of the claims in any of our currently pending or future patent applications, and we can offer no assurance that in the event any claims in any of our issued patents are challenged by one or more third parties, that any court or patent authority ruling on such challenge will determine that such patent claims are valid and enforceable or sufficiently broad in scope to protect our proprietary rights. Also, the nature of the process for obtaining patents and the extent of protection provided by patent laws varies from country to country. We can offer no assurance, therefore, that the issuance to us in one country of a patent covering an invention will be followed by the issuance to us in other countries of patents covering the same invention or that any judicial interpretation of such patents will be uniform in multiple jurisdictions. Furthermore, even if our patents are determined to be valid, enforceable and broad in scope, we can offer no assurance that competitors will not be able to design around such patents.

Government Regulation

     We believe our delivery systems, when used in conjunction with therapeutic pharmaceuticals, will be subject to drug and biological product approval requirements. In the United States, biological products, such as therapeutic proteins and peptides, generally are subject to the same FDA regulatory requirements as other drugs, although some differences exist. For example, for some biological products a biologic license application (BLA) is submitted for approval for commercialization instead of the new drug application (NDA) used for other drugs. Also, unlike drug products, some biological products are subject to FDA lot-by-lot release requirements and those approved under a BLA currently cannot be the subject of abbreviated new drug applications (ANDAs). Insulin, which is regulated as a drug product, typically has not been the subject of ANDAs. However, the FDA is working on a variety of issues pertaining to the possible development of generic versions of insulin and there can be no assurance that this type of submission will continue to be unavailable for insulin. Additionally, our delivery systems likely will be regulated by the FDA as ‘combination products’ if they are used together with a biologic or medical device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of both components.

     Photochromic eyeglass lenses are regulated by the FDA as medical devices.

     The design, testing, manufacturing and marketing of new or substantially modified drugs biological products or medical devices must be approved or cleared by regulatory agencies under applicable laws and regulations, the requirements of which may vary from country to country. This regulatory process is lengthy, expensive and uncertain. In the United States, the FDA regulates such products under various federal statutes, including the Federal Food Drug and Cosmetic Act and the Public Health Service Act. Similar requirements exist in the Member States of the European Union. There can be no assurance that we or our collaborative partners will be able to obtain such regulatory approvals or clearances on a timely basis, if at all, for any products under development. Delays in receipt or failure to receive such approvals or clearances, the revocation of previously received approvals or clearances, or failure to comply with existing or future regulatory requirements could have a material adverse effect on our business, financial condition and results of operations.

New Drug and Biological Product Development and Approval Process

     United States

     Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture, and marketing of biological and drug products and in ongoing research and product development activities. The products of all of our pharmaceutical and biotechnology partners will require regulatory approval by governmental agencies prior to commercialization. In particular, these products are subject to manufacturing according to stringent cGMP quality principles, and rigorous, pre-clinical and clinical testing and other pre-market approval requirements by the FDA and regulatory authorities in other countries. In the United States, various statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, record keeping and marketing of pharmaceutical and biological products. The lengthy process of seeking these approvals, and the subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources.

     The FDA’s statutes, regulations, or policies may change and additional statutes or government regulations may be enacted which could prevent or delay regulatory approvals of biological or drug products. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad.

     Regulatory approval, when and if obtained, may be limited in scope. In particular, regulatory approvals will restrict the marketing of a product to specific uses. Approved biological and other drugs, as well as their manufacturers, drug products are subject to ongoing review (pharmacovigilance: monitoring for adverse reactions, regulation, including requirements and restrictions related to record keeping and reporting, FDA approval of certain changes in manufacturing processes or product labeling, product promotion and advertising, and pharmacovigilance, which includes monitoring and reporting adverse reactions, maintaining safety measures, and conducting dossier reviews for marketing authorization renewal). Discovery of previously unknown problems with these products may result in restrictions on their manufacture, sale or use, or in their withdrawal from the market. Failure to comply with regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension of production or injunction, as well as other actions affecting the commercial prospects of our pharmaceutical and biotechnology partners’ potential products or uses or products that incorporate our technologies. Any failure by our pharmaceutical and biotechnology partners to comply with permanently emerging current or new and changing regulatory obligations, and any failure to obtain and maintain, or any delay in obtaining, regulatory approvals, could materially adversely affect our business.

     The process for new drug and biological product development and approval has many steps, including:

     Chemical and Formulation Development

     Pharmaceutical formulation taking into account the chemistry and physical characteristics of the drug or biological substance is the beginning of a new product. If initial laboratory experiments reveal that the concept for a new drug or biological product looks promising, then, a variety of further development steps and tests complying with internationally recognized guidance documents will have to be continued, in order to provide for a product ready for testing in animals and, after sufficient animal test results, also in humans.

     Concurrent with pre-clinical studies, clinical trials companies must continue to develop information about the properties of the drug product and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and the manufacturer must develop and validate methods for testing the quality, purity and potency of the final products. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life.

     Pre-Clinical Testing

     Once a biological or drug candidate is identified for development, the drug candidate enters the pre-clinical testing stage. This includes laboratory evaluation of product chemistry and formulation, as well as animal studies of pharmacology (mechanism of action, pharmacokinetics) and toxicology which may have to be conducted over lengthy periods of time, to assess the potential safety and efficacy of the product as formulated. Pre-clinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring such studies to be replicated. In some cases, long-term pre-clinical studies are conducted while clinical studies are ongoing.

     Investigational New Drug Application

     USA: The entire body of chemical or biochemical, pharmaceutical and pre-clinical development work necessary to administer investigational drugs to human volunteers or patients is summarized in an investigational new drug (IND) application to the FDA. The IND becomes effective if not rejected by the FDA within 30 days after filing. There is no assurance that the submission of an IND will eventually allow a company to commence clinical trials. All clinical trials must be conducted under the supervision of a qualified investigator in accordance with good clinical practice regulations to ensure the quality and integrity of clinical trial results and data. These regulations include the requirement that, with limited exceptions, all subjects provide informed consent. In addition, an institutional review board (IRB), composed primarily of physicians and other qualified experts at the hospital or clinic where the proposed studies will be conducted, must review and approve each human study. The IRB also continues to monitor the study and must be kept aware of the study’s progress, particularly as to adverse events and changes in the research. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if adverse events occur. Failure to adhere to good clinical practices and the protocols, and failure to obtain IRB approval and informed consent, may result in FDA rejection of clinical trial results and data, and may delay or prevent the FDA from approving the drug for commercial use.

     European Union: The European equivalent to the IND is the Investigational Medicinal Product Dossier (IMPD) which likewise has to contain pharmaceutical, pre-clinical and, if existing, previous clinical information on the drug substance and product. The intended clinical trial must be authorized by the regulatory authority(ies) of each country where the trial is intended to be run and will be based on the favorable attitude of the Ethics Committee(s) of each country (EU equivalent to IRBs) before trial authorization will be given by the agency(ies) concerned.

     Clinical Trials

     Typically, clinical testing involves the administration of the drug or biological product first to healthy human volunteers and then to patients with conditions needing treatment under the supervision of a qualified principal investigator, usually a physician, pursuant to an FDA reviewed (via the IND submission) ‘protocol,’ or clinical plan. This latter details matters such as a description of the condition to be treated, the objectives of the study, a description of the patient population eligible for the study and the parameters to be used to monitor safety and efficacy.

     Clinical trials are time-consuming and costly, and typically are conducted in three sequential phases, which sometimes may overlap. Phase I trials consist of testing the product in a small number of patients or normal volunteers, primarily for safety, in one or more dosages, as well as characterization of a drug’s pharmacokinetic and/or pharmacodynamic profile. In phase II, in addition to safety, the product is studied in a patient population to evaluate the product’s efficacy for the specific, targeted indications and to determine dosage tolerance and optimal dosage. Phase III trials typically involve additional testing for safety and clinical efficacy in an expanded patient population at geographically dispersed sites. With limited exceptions, all patients involved in a clinical trial must provide informed consent prior to their participation. Meeting clinical endpoints in early stage clinical trials does not assure success in later stage clinical trials. Phase I, II, and III testing may not be completed successfully within any specified time period, if at all.

     The FDA monitors the progress of each clinical trial phase conducted under an IND and may, at its discretion, reevaluate, alter, suspend or terminate clinical trials at any point in this process for various reasons, including a finding that patients are being exposed to an unacceptable health risk or a determination that it is unethical to continue the study. The FDA can also request additional clinical trials be conducted as a condition to product approval. The IRB also may order the temporary or permanent discontinuance of a clinical trial at any time for a variety of reasons, particularly if safety concerns arise. Such holds can cause substantial delay and in some cases may require abandonment of product development. These clinical studies must be conducted in conformance with the FDA’s bioresearch monitoring regulations and/or internationally recognized guidance (such as ICH, or International Conference on Harmonization).

     New Drug Application or Biological License Application

     After the completion of the clinical trial phases of development, if the sponsor concludes that there is substantial evidence that the drug or biological candidate is effective and that the drug is safe for its intended use, an NDA or BLA may be submitted to the FDA. The application must contain all of the information on the drug or biological candidate gathered to that date, including data from the pre-clinical and clinical trials, information pertaining to the preparation of the drug or biologic, analytical methods, product formulation, details on the manufacture of finished products, proposed product packaging, labeling and stability (shelf-life). NDAs and BLAs are often over 100,000 pages in length. Submission of an NDA or BLA does not assure FDA approval for marketing.

     The FDA reviews all NDAs and BLAs submitted before it accepts them for filing (the U.S. prerequisite for dossier review). It may refuse to file the application and request additional information rather than accepting an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use. As part of this review, the FDA may refer the application to an appropriate advisory committee, typically a panel of clinicians, for review, evaluation and a recommendation. The FDA is not bound by the recommendation of an advisory committee. Under the Prescription Drug User Fee Act (PDUFA), submission of an NDA with clinical data requires payment of a fee. In return, the FDA assigns a goal of 10 months from acceptance of the application to return of a first ‘complete response,’ in which the FDA may approve the product or request additional information. There can be no assurance that an application will be approved within the performance goal timeframe established under PDUFA, if at all. If the FDA’s evaluation of the NDA or BLA is not favorable, the FDA usually will outline the deficiencies in the submission and request additional testing or information. Notwithstanding the submission of any requested additional information, or even in lieu of asking for additional information, the FDA may decide that the marketing application does not satisfy the regulatory criteria for approval or issue a “not-approvable” letter, communicating the agency’s refusal to approve the application.

     FDA approval of an NDA or BLA will be based, among other factors, on the agency’s review of the pre-clinical and clinical data submitted, a risk/benefit analysis of the product, and an evaluation of the manufacturing processes and facilities. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA has substantial discretion in the approval process and may disagree with an applicant’s interpretation of the data submitted in its NDA. Among the conditions for NDA or BLA approval is the requirement that each prospective manufacturer’s quality control and manufacturing procedures conform to cGMP standards and requirements. Manufacturing establishments often are subject to inspections prior to NDA or BLA approval to assure compliance with cGMPs and with manufacturing commitments made in the relevant marketing application.

     Other Countries

     Whether or not FDA approval has been obtained, approval of a pharmaceutical product by comparable regulatory authorities must be obtained in any other country prior to the commencement of marketing of the product in that country. The approval procedure may vary from country to country, can involve additional testing, and the time required may differ from that required for FDA approval. Under European Union regulations, product approval can be obtained for a period of five years, renewable subject to certain procedures through either a centralized or decentralized procedure depending on the nature and type of drug. Certain designated drugs are required to use the centralized procedure (mandatory: biologics, biotech and certain indications such as cancer, AIDS, diabetes and CNS; optional for various types of innovations). All others have the option to use the mutual recognition procedure, where approval is first obtained in one European Union country that then acts as a reporter for extending the product’s approval in other European Union countries, or the new decentralized procedure where submission is concomitant in all desired countries, one of them taking care of the dossier intensively and coordinating activities. To the extent possible, clinical trials of our products are designed to develop a regulatory package sufficient for multi-country European Union approval.

     Regulatory approval of prices for certain drugs is required in France and in most other countries outside the United States. In particular, certain European countries will condition the reimbursement of a product by the countries’ medical regulatory authorities on the agreement of the seller not to sell the product for more than a certain price in that country or by unilateral decision of the medical regulatory authorities and to the inscription of a product on a list of reimbursable products. Related pricing discussions and ultimate governmental approvals can take several months to years. Some countries require periodic pricing updates and renewals at intervals ranging from two to five years. We cannot assure you that, if regulatory authorities establish lower prices for any product incorporating our technology in any one European country, this will not have the practical effect of requiring our collaborative partner correspondingly to reduce its prices in other European countries. We can offer no assurance that the resulting prices would be sufficient to generate an acceptable return on our investment in our products.

Regulation of Combination Drugs

     Medical products containing a combination of drugs, biological products or medical devices may be regulated as ‘combination products’ in the United States. A combination product generally is defined as a product comprising components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). Each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic or device.

     In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of both components. The determination whether a product is a combination product or two separate products is made by the FDA on a case-by-case basis. It is possible that our delivery technologies, when coupled with a drug, biologic or medical device component, could be considered and regulated by the FDA as a combination product.

     In the European Union, “Drug Combinations” are drug products containing 2 or more drug substances each of which has to contribute a proven advantage of therapy (e.g. synergism, less adverse reactions) and are subject to drug regulations like all others. Products combining drug substances or drugs with a device would likely be subject to device and/or drug regulations, depending on the individual case.

Marketing Approval and Reporting Requirements

     If the FDA approves an NDA or BLA, the product becomes available for physicians to prescribe. The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval to develop additional information regarding the safety of a product. These studies may involve continued testing of a product and development of data, including clinical data, about the product’s effects in various populations and any side effects associated with long-term use. In addition, the FDA may require distribution to patients of a medication guide for prescription products that the agency determines pose a serious and significant health concern in order to provide information necessary to patients’ safe and effective use of such products.

     In the European Union, phase IV post-marketing studies are often run by companies in order to obtain further information on product efficacy and positioning on the market in view of competitors.

Post-Marketing Obligations

     Any products manufactured and/or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including record keeping requirements, reporting of adverse experiences with the product, submitting other periodic reports, drug sampling and distribution requirements, notifying the FDA and gaining its approval of certain manufacturing or labeling changes, complying with certain electronic records and signature requirements, submitting periodic reports to the FDA, maintaining and providing updated safety and efficacy information to the FDA, and complying with FDA promotion and advertising requirements.

     Drug and biologics manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and to list their products with the FDA. The FDA periodically inspects manufacturing facilities in the United States and abroad in order to assure compliance with the applicable cGMP regulations and other requirements. Facilities also are subject to inspections by other federal, foreign, state or local agencies. In complying with the cGMP regulations, manufacturers must continue to expend time, money and effort in record keeping and quality control to assure that the product meets applicable specifications and other post-marketing requirements. Failure of the company or our licensees to comply with FDA’s cGMP regulations or other requirements could have a significant adverse effect on the company’s business, financial condition and results of operations.

     Also, newly discovered or developed safety or efficacy data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, or even in some instances, revocation or withdrawal of the approval. Violations of regulatory requirements at any stage, including after approval, may result in various adverse consequences, including the FDA’s delay in approving or refusal to approve a product, withdrawal or recall of an approved product from the market, other voluntary or FDA-initiated action that could delay or restrict further marketing, and the imposition of criminal penalties against the manufacturer and NDA holder. In addition, later discovery of previously unknown problems may result in restrictions on the product, manufacturer or NDA holder, including withdrawal of the product from the market. Furthermore, new government requirements may be established that could delay or prevent regulatory approval of our products under development, or affect the conditions under which approved products are marketed.

     In the European Union, stringent pharmacovigilance regulations oblige companies to collect adverse reactions and other eventual supplementary information, report to authorities at regular intervals and take adequate safety measures agreed with regulatory agencies as necessary.

Patent Restoration and Exclusivity

     Under the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, a portion of a product’s patent term that is lost during a product’s clinical development and application review by the FDA may be restored. Patent term restoration can return up to five years of patent term for a patent that covers a new product or its use. The patent term restoration period is generally one-half the time between the effective date of the IND and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60 days of approval. The maximum period of restoration cannot exceed 5 years, or restore the total remaining term of the patent to greater than 14 years from the date of FDA approval of the product. The application for patent term extension is subject to approval by the U.S. Patent and Trademark Office (USPTO), in conjunction with the FDA. It usually takes at least six months to obtain approval of the application for patent term extension, and there can be no guarantee that the application will be granted.

     The Hatch-Waxman Act also created an abbreviated FDA review process for generic and modified versions of pioneer (brand name) drug products, along with a period of statutory protection, known as exclusivity, for new drugs approved under an NDA by the FDA. After approval of a ‘new chemical entity,’ the FDA may not, for a period of five years, accept an ANDA for a generic version of the drug, or an NDA for a drug that is a modification of the innovator and seeks to rely, to some degree, on FDA’s finding that the innovator is safe and effective. This latter type of submission is known as a “505(b)(2) NDA.” After the period of exclusivity has expired, the ANDA process permits a competitor to obtain marketing approval for a generic version of the innovator by showing that the generic product is bioequivalent to the innovator, and without submitting data demonstrating the product’s safety and effectiveness. Similarly, a 505(b)(2) NDA can also then be submitted for a drug that reflects a modification of the innovator product, but seeks to rely on FDA’s previous findings as part of the data demonstrating the new product’s safety and efficacy.

     Hatch-Waxman also provides three years of exclusivity for NDAs that, although not for a new chemical entity, rely on the results of new clinical investigations (other than bioavailability studies) that were essential to the FDA’s approval of the application. Often, this applies to NDAs and NDA supplements seeking approval for new indications, dosage forms, strengths, or conditions of use of previously approved products. As a general proposition, the Hatch-Waxman exclusivities do not bar the approval of full NDAs – that is, NDAs containing all the clinical and other data necessary for FDA’s finding of safety and efficacy – for the same active ingredient. In addition, the three-year exclusivity for new clinical trials only bars applications for a product with the same characteristic as what required the new clinical trials. For example, Coreg CR received three-year exclusivity for the clinical trials that demonstrated the safety and efficacy of the new, controlled-release dosage form; that exclusivity blocks other controlled-release products.

     When an innovator product is approved, the applicant must identify for the FDA certain patents related to the drug that is the subject of the approval. When an ANDA or 505(b)(2) NDA is submitted, the sponsor must notify the holder of the NDA for the innovator drug that is the reference product and the holder of patents listed with that innovator product, and make certifications regarding the patents. If the sponsor asserts that the patents are invalid or not infringed by the manufacture, sale or use of the new product (this is known as a “Paragraph IV certification”), the ANDA or 505(b)(2) NDA can be submitted four years into the five-year exclusivity. In addition, such a certification allows the NDA or patent holder to bring a patent infringement suit, and that suit imposes a 30-month stay on approval of the ANDA or 505(b)(2) NDA. The discovery, trial and appeals process in such suits can take several years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period, the stay is lifted and the FDA’s review of the application may proceed. If a court finds the patent valid and infringed, the ANDA or 505(b)(2) application may not be made approved until the expiration of the patent. In addition, if the NDA holder or patent owner chooses not to sue such an applicant within the 45-day window, the FDA may approve the ANDA or 505(b)(2) application whenever all of the other requirements for approval are met.

     The protection provided by listed patents and Hatch-Waxman exclusivities can be extended by six months if a company studies the drug in a pediatric population in response to a written request from the FDA. The trial results do not need to show efficacy in the pediatric population studied; rather, if the trial is deemed to fairly respond to the request, the additional protection is granted. Coreg CR has received such pediatric exclusivity, which extends the three-year new clinical trial exclusivity it previously obtained, as well as the protection of the listed patents. The statutory provision permitting the award of pediatric exclusivity expires on October 1, 2007, and there can be no guarantee that Congress will reauthorize this provision, or do so without significant changes.

     The Hatch-Waxman construct applies only to conventional chemical drug compounds, sometimes referred to as small molecule compounds. There is no such process under current law for biological products approved under a BLA, such as growth factors, interferons and certain other proteins. The FDA generally has asserted that it lacks statutory authority to implement an abbreviated approval pathway for generic or “follow-on” biological products. Some have disagreed with this assessment, suggesting that FDA has the necessary authority. In addition, there have been legislative proposals in Congress to explicitly grant FDA such authority. If the law is changed or if the FDA otherwise concludes that it has authority to approve follow-on biologics, such an abbreviated approval process could adversely affect biological products that incorporate our technologies.

Regulation of Medical Devices

     United States

     In the United States, medical devices are classified into Class I, II or III on the basis of the controls deemed by the FDA to be reasonably necessary to ensure their safety and effectiveness. Class I devices are subject to general controls (e.g., labeling, and adherence to cGMPs) and Class II devices are subject to special controls (e.g., performance standards, postmarket surveillance, patient registries, and FDA guidelines). Generally, Class III devices are those which must require premarket approval by the FDA to ensure their safety and effectiveness (e.g., life-sustaining, life-supporting and implantable devices or those found not to be substantially equivalent to legally marketed devices).

     Other Countries

     For medical devices, since January 1, 1995, European Union countries are required to put in effect certain Medical Devices Directives (MDD). This legislation includes, among others, requirements with respect to the design, safety, performance and manufacture of products. Under the system established by the MDD, medical devices must qualify for CE Marking by June 14, 1998. All new medical devices put on the market after June 14, 1998 must meet the MDD requirements. Devices are subject to, in addition to existing or future European Union or other countries’ legislation, continued national regulation on pricing and reimbursement that may vary from country to country.

     In order to qualify for CE Marking, the manufacturer must comply with the safety and performance requirements of the MDD. In order to demonstrate compliance, the manufacturer must undergo conformity assessment that depends on the class of the product. Once all the necessary conformity assessment tasks have been completed, CE Marking may be affixed on the products concerned. Although member countries must accept for marketing medical devices bearing a CE Marking without imposing further requirements related to product safety and performance, national regulatory authorities who are required to enforce compliance with requirements of the MDD can restrict, prohibit and recall CE Marked products if they are unsafe. Member countries can impose additional requirements as long as they do not violate the MDD or constitute technical barriers to trade. Within the European Union, premarket compliance for certain devices must be supported by clinical data of a type and to the extent set out by the European Union directives and applicable member country regulations. Following marketing, a strict vigilance system involving the reporting of incidents and the appropriate measures to deal with these incidents exists in certain European Union countries, including France.

Other Regulation

     Controlled Substances Act. Our Trigger-Lock™ technology is designed to control the release of narcotics and other active ingredients subject to abuse. Narcotics are “controlled substances” under the Controlled Substances Act. The federal Controlled Substances Act (CSA), Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, regulates the manufacture and distribution of narcotics and other controlled substances, including stimulants, depressants and hallucinogens. The CSA is administered by the Drug Enforcement Administration (DEA), a division of the U.S. Department of Justice, and is intended to prevent the abuse or diversion of controlled substances into illicit channels of commerce.

     Any person or firm that manufactures, distributes, dispenses, imports, or exports any controlled substance (or proposes to do so) must register with the DEA. The applicant must register for a specific business activity related to controlled substances, including manufacturing or distributing, and may engage in only the activity or activities for which it is registered. The DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to comply with relevant DEA regulations, particularly as manifested in the loss or diversion of controlled substances, can result in regulatory action including civil penalties, refusal to renew necessary registrations, or proceedings to revoke those registrations. In certain circumstances, violations can lead to criminal prosecution. In addition to these federal statutory and regulatory obligations, there may be state and local laws and regulations relevant to the handling of controlled substances or listed chemicals.

     cGMP. Its rules apply to the manufacturing of drugs and medical devices. Our manufacturing facilities and laboratories are subject to inspection and regulation by French regulatory authorities and may also be subject to the United States and other countries’ regulatory agencies. Mutual recognition agreements for government inspections exist between the United States, the European Union, Canada, Australia and New Zealand.

     In addition to regulations enforced by the FDA, we are also subject to French, U.S. and other countries’ rules and regulations governing permissible laboratory activities, waste disposal, handling of toxic, dangerous or radioactive materials and other matters. Our research and development involves the controlled use of hazardous materials, chemicals, viruses and various radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by French, U.S. and other foreign rules and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated.

Healthcare Reimbursement

     In both U.S. and foreign markets, sales of our potential products, if any, will depend in part on the availability of reimbursement by third-party payers, such as government health administration authorities, private health insurers and other organizations. The U.S. market for pharmaceutical products is increasingly being shaped by managed care organizations, pharmacy benefit managers, cooperative buying organizations and large drugstore chains. Third-party payers are challenging the price and cost effectiveness of medical products and services. Uncertainty particularly exists as to the reimbursement status of newly approved healthcare products. There can be no assurance reimbursement will be available to enable us to maintain price levels sufficient to realize an appropriate return on our product development investment. Legislation and regulations affecting the pricing of pharmaceuticals may change before our proposed products are approved for marketing and any such changes could further limit reimbursement for medical products and services.

Competition

     We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing drug delivery systems. Some of these competitors are also our business partners.

     There are other companies developing sustained release drug delivery systems and oral delivery systems. There could be new chemical entities that are being developed that, if successful, could compete against our technologies or products. Among the many experimental therapies being tested in the United States and in Europe, there may be some that we do not now know of that may compete with our drug delivery systems or products in the future. These chemical entities and new products may turn out to be safer or may work better than our technologies or products. Our collaborators could choose a competing drug delivery system to use with their drugs instead of one of our drug delivery systems.

     Many of our competitors have substantially greater experience and research and development, manufacturing, marketing, financial and managerial resources than we do. Moreover, there can be no assurance that our competitors will not obtain patent protection or other intellectual property rights that would make it difficult or impossible for us to compete with their products. Furthermore, acquisitions of competing drug delivery companies by large pharmaceutical companies could enhance our competitors’ resources. Accordingly, our competitors may succeed in developing competing technologies and products, obtaining regulatory approval and gaining market share for these products more rapidly than we do.

     Further, major technological changes can happen quickly in the biotechnology and pharmaceutical industries. Such rapid technological change, or the development by our competitors of technologically improved or different products, could render our drug delivery systems obsolete or noncompetitive.

     Additionally, the competitive nature of our industry could adversely affect market acceptance of our products or the use of our drug delivery technologies. Our products and technologies may not gain market acceptance among physicians, patients, healthcare payers and the medical community. The degree of market acceptance of any product candidate that we develop will depend on a number of factors, including:

	•		demonstration of its clinical efficacy and safety;
	•		its cost-effectiveness;
	•		its potential advantage over alternative treatment methods; and
	•		the marketing and distribution support it receives.

Description of Property

     Our corporate headquarters and the research center are located in Venissieux, France (a suburb of Lyon) in six adjacent leased facilities totaling approximately 60,000 square feet. One building of approximately 13,000 square feet houses research laboratories, including equipment dedicated to polymer characterization and analytical research. The lease on this facility currently expires in 2009. We intend to renew it. A second facility comprising approximately 13,000 square feet houses equipment dedicated to our Micropump technology. We have renewed the lease on this facility which expires in 2015. The third and fourth facilities of approximately 11,000 square feet house our administrative offices. The leases on these facilities expire from 2010 to 2013. The fifth facility of approximately 6,800 square feet houses analytical laboratories and quality control, with a lease expiring at the end of 2012. The sixth facility of approximately 20,000 square feet houses a biological laboratory and research laboratories with equipment for organic synthesis and polymerization, polymer formulation and small scale processing. The lease on this facility expires end of 2014.

     In 1996, we acquired a pharmaceutical production facility which now comprises approximately 60,000 square feet located in Pessac, France from SmithKline. The plant is housed on a 470,000 square foot lot in an industrial park not far from the Bordeaux airport. Since acquiring the plant, we have added a new manufacturing site with spray-coating equipment and a clean room for the synthesis of biopolymers. The facility has been audited by European and US drug agencies and is, we believe, cGMP compliant. It is qualified to manufacture pharmaceutical products that can be sold in most countries in Europe and the US. The value of the facility is recorded in our financial books at the value of the liabilities corresponding to the retirement indemnities of the plant staff that we assumed at the time of the plant purchase, plus the additional investments made by us, less the depreciation and appropriate amortization.

     In 2004, we built a new facility of 16,000 square feet for a total purchase price of $10.3 million. This new building included 8,600 square feet for the Medusa technology with a new cGMP pilot plant, extended synthesis capacity and increased capacity to manufacture qualification and phase III lots at 10% of the commercial batch size.

     In 2006, we completed the expansion of our facilities in preparation for the manufacture of Coreg CR microparticles for GlaxoSmithKline as well as other Micropump enabled formulations. The new facility comprises 6,800 square feet and houses two suites of equipment, as well as a dedicated warehouse, analytical control laboratory and a technical area with air compressor units, refrigeration units for solvents, and heat boiler. The new Micropump facility was constructed at a cost of $8.2 million and has been manufacturing commercial quantities of the product since the last quarter of 2006 on a 24 hours a day, 7 days a week basis.

     In the last quarter of 2006, we commenced the expansion of our Micropump Pilot Development facilities increasing the available area by 14,300 square feet and renovating a further 4,500 square feet. The new facility will house administrative offices and process development areas which can be utilized for the production of both clinical and commercial batches, thus increasing our production capacity from two lines to three. GSK will partly sponsor the extension of these facilities and will have exclusive use of part of this equipment, in order to increase the production capacity of Coreg CR microparticles.

          ITEM 4A. Unresolved Staff Comments

N/A.

          ITEM 5. Operating and Financial Review and Prospects

     The following should be read in conjunction with ‘Item 3. Key Information’ and the Company’s Financial Statements and the Notes related thereto appearing elsewhere in this Annual Report. See also ‘Item 11. Quantitative and Qualitative Disclosures About Market Risk.’

Overview

     Flamel is a biopharmaceutical company principally engaged in the development of two unique polymer based delivery systems for medical applications. Our core technologies are focused on improving delivery properties of existing products. We have established long-term development and commercialization partnerships with leading biopharmaceutical companies to maximize the breadth of our technology and leverage the capabilities of our partners.

     2006 has been a critical year for the Company as a result of the success of our partnership with GlaxoSmithKline (GSK) for the development of Coreg CR. This partnership along with other feasibility initiatives with undisclosed partners has enabled a stability of revenues in 2006 and revenues from the supply of commercial quantities of Coreg CR microparticles to GSK as of the final quarter. The Company has maintained a tight control on expenses to ensure efficient and effective use of funds for the long term benefit of the company and, as a result, operating expenses have decreased compared with 2005. The Company has adopted, as of January 1, 2006, FAS 123R – Stock Based Compensation, using the modified prospective method, which has resulted in the recognition of $10.0 million of non-cash expenses in 2006. Under the transition method, compensation cost in 2006 includes: (i) compensation cost for all share-based payments granted prior to but not vested as of January 1, 2006, and (ii) compensation cost for all share-based payments granted in 2006.

     The Company has continued to achieve scientific success with both technological platforms and notably the development in 2006 of a unique polymer for our Medusa platform. Investments in our facilities were pursued in 2006 in order to meet the demands of our key partners and will continue to be pursued through the renovation and extension of our existing Micropump Development facilities at Pessac in 2007.

     As in previous years, the majority of the Company’s expenses were incurred in Euros. However, a significant portion of revenues were, and will continue to be, denominated in U.S. dollars, see ‘Item 11. Quantitative and Qualitative Disclosures about Market Risk’. The conversion of the Company’s financial accounts to U.S. dollars is calculated in accordance with the value of the Euro to the U.S. dollar. See ‘Item 3. Key Information – Exchange Rates. The relative stability of the average value of the Euro relative to the U.S. dollar in 2005 and 2006 enables a reasonable comparison of the Statement of Operations. However, the significant increase in the value of the Euro relative to the U.S. dollar (11.6%) results in a corresponding increase in amounts represented in the Balance Sheet as of December 31, 2006 compared with December 31, 2005. The company does not engage in substantial hedging activities with respect to the risk of exchange rate fluctuations, except it does, from time to time, purchase Euros against invoiced dollar receivables. There is no outstanding hedging agreement as of December 31, 2006.

     The Company continues to benefit from a solid cash position which has enabled to continue to invest both in internal research programs and in the infrastructure required to execute these programs and those of our partners.

     Flamel’s business is subject to substantial risks, including the uncertainties associated with the research and development of new products or technologies, the length and uncertainty linked to the results of clinical trials and regulatory procedures, uncertainties relating to collaborative arrangements with large companies, difficulties in the scale-up and manufacturing of its products, and the uncertainty relating to the market acceptance of new products based on its technologies. The time required for the Company to achieve sustained profitability, and consequently, the amount of future losses, is highly uncertain. Operating losses may also fluctuate from quarter to quarter as a result of differences in timing of revenues recognized or expenses incurred. See ‘Item 3. Key Information — Risk Factors.’

     The Company has incurred substantial losses since its inception, and through December 31, 2006, had an accumulated deficit of approximately $110.4 million. Flamel expects to continue its investment in its research and development activities and to maintain its primary facilities and business infrastructure. Thus, there can be no assurance that the Company will not continue to incur losses in the short term. In the future, we expect our product sales and costs of goods sold to increase as a result of an increase in manufacturing activities for GlaxoSmithKline. We also expect an increased revenue stream from royalties as a result of the approval and launch of Coreg CR by GlaxoSmithKline in the first quarter of 2007, which marks the first commercial utilization of Flamel’s Micropump technology.

Critical Accounting Policies

     Revenue Recognition

     The Company recognizes revenue from contract arrangements, product sales and royalties earned. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered elements. The consideration received is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units.

     Contract revenue generally includes upfront licensing fees, milestone payments and reimbursements of research and development costs. Non-refundable technology access fees received from collaboration agreements that require the Company’s continuing involvement in the form of development efforts are recognized as revenue ratably over the development period. The Company recognizes milestone-related revenues only when performance of the milestone under the terms of the collaboration is achieved and there are no further performance obligations. Research and laboratory analysis services revenue is recognized as the research and development work is performed. Costs incurred under these contracts are considered costs in the period incurred. Payments received in advance of performance are recorded as deferred revenue and recognized as revenue as services are rendered.

     The Company receives financial support for various research and investment projects from governmental agencies with specified conditions to be met. Revenue from conditional grants is recognized in other income when all conditions stated in the grant have been met and the funding has been received.

     The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable, and collectibility is reasonably assured.

     The Company receives royalty revenues under a license agreement with Corning, which sells products based on technology developed by the Company. There are no future performance obligations on the part of the Company under this license agreement. The license agreement provides for the payment of royalties to the Company based on sales of the licensed product. The Company records these royalty revenues based on actual sales to third parties that occurred during the relevant period.

     The Company signs feasibility study agreements. Revenue is recognized over the term of the agreement as services are performed.

     The Company receives financial support for capital investment programs from partners. Revenue from these operations is amortized on a pro-rata basis over the expected life of the related assets and reflected as an offset of the depreciation of the related assets in the consolidated statements of operations.

Results of Operations

     Years Ended December 31, 2006, 2005 and 2004

     Operating Revenues

     The Company had total revenues of $23.0 million in 2006, $23.6 million in 2005 and $55.4 million in 2004.

				2004				2005				2006
LICENSE AND RESEARCH REVENUES					50.9				20.8				20.3
RESEARCH					20.8				15.4				13.4
Research		Servier			0.2
		GSK Coreg CR			6.4				8.6				9.6
		BMS			8.0
		TAP Lansoprazole			4.9				6.8
		Biovail Genvir			0.6
		Undisclosed Partners			0.7								3.8
LICENSES					30.1				5.4				6.9
Up Front Payment		Servier			1.4
		GSK Coreg CR			0.8				0.8				0.2
		BMS			19.9
		TAP Lansoprazole			0.1				0.9
		Biovail Genvir			0.2				0.2
		Undisclosed Partners			0.1								0.7
Milestones		GSK Coreg CR			2.0				2.0				6.0
		BMS			5.1
		TAP Lansoprazole			0.5				1.5
TOTAL					50.9				20.8				20.3
		Servier			1.6
		GSK Coreg CR			9.2				11.4				15.8
		BMS			33.0
		TAP Lansoprazole			5.5				9.2
		Biovail Genvir			0.8				0.2
		Undisclosed Partners			0.8								4.5

     License and research revenues in total in 2006 are comparable with 2005 although the termination of the licence agreement with TAP in September 2005 has been compensated for by research and license revenues with undisclosed partners and increased research and development revenues from GSK.

     Research and development revenues in 2006 consisted primarily of $9.6 million from GSK, and $3.8 million from undisclosed partners. Research and development revenues in 2005 consisted primarily of $8.6 million from GSK, and $6.8 million from TAP. Research and development revenues in 2004 consisted primarily of $8 million from Bristol-Myers Squibb, $6.4 million from GSK, and $4.9 million from TAP.

     License revenue in 2006 consisted primarily of $6.2 million from GSK (of which $0.2 million represents amortization of up-front payments). Recognition of the amortization of up-front payments is calculated according to the average exchange rate during the period of recognition. License revenues in 2005 consisted primarily of $2.8 million from GSK (of which $0.8 million represents amortization of up-front payments) and $2.4 million from TAP. License revenue in 2004 consisted primarily of $25 million from Bristol-Myers Squibb (of which, $19.9 million represents amortization of up-front payments, including the unamortized portion at December 15, 2004 which was recognized upon the effective date of the cancellation of the contract with Bristol-Myers Squibb), $2.8 million from GSK (of which $0.8 million represents amortization of up-front payments) and $1.4 million from Servier (all of which represents amortization of up-front payments).

     In 2006, product sales and services revenues totaled $2.1 million all of which relates to the sale of Coreg CR microparticles to GSK. In 2005, product sales and services revenues totaled $1.8 million of which $0.1 million related to the manufacture of Cimetidine and Tagamet for GlaxoSmithKline and $1.7 million from clinical batches and toll manufacturing with various customers. In 2004, product sales and services revenues totaled $3.8 million of which $0.12 million relate to the manufacture of Cimetidine and Tagamet for GlaxoSmithKline and $3.7 million from clinical batches and toll manufacturing with various customers.

     Other revenues of $ 0.7 million in 2006 consisted primarily of royalties from Corning related to the sale of photochromic lenses, incorporating Flamel’s technology. Other revenues of $1.0 million in 2005 and $0.8 million in 2004 consisted primarily of royalties from Corning.

     Operating Expenses

     The Company had total costs and expenses of $61.9 million in 2006, $64.4 million in 2005 and $46.6 million in 2004.

     In 2006, research and development costs represented the most significant operating expenses of the Company. These totaled $38.2 million in 2006, $47.3 million in 2005 and $35.4 million in 2004. In 2006 research and development costs include $3.9 million of FAS 123R options-related expense. Nevertheless, research and development costs remain in excess of the Company’s license and other revenues, but to a lesser degree than in 2005. The company continues to invest in pre-clinical and clinical studies on products in early phases of development. Since the Company’s base of operations is in France, these costs are denominated in Euros. Consequently, the fluctuation in the value of the Euro against the U.S. dollar can result in higher dollar-denominated costs, although this variable has had limited impact on results in 2006 and 2005 as a result of the stability of the average exchange rate. During the course of 2006 the Company has continued to pursue its research and development activities on both platforms on early phase projects, but equally on new projects and initiatives which are considered to enhance the attractiveness of our technology platforms for potential partners.

     In 2006, research and development costs decreased by approximately $9.1 million compared to 2005 (or 19.2%) and by $13 million (or 27.5%) prior to inclusion of FAS 123R options-related expense amounting to $3.9 million. Research and development costs in 2006 represent the cost of self-funded programs such as interferon-alpha, human growth hormone and the development of a unique polymer for the Medusa platform. The increase in research and development costs in 2005 compared to 2006 and 2004 was due to the active pursuit of ongoing partnerships and the decision to pursue into 2005 the conclusion of studies already commenced on Basulin following the notice of termination of the agreement in late 2004. The number of employees dedicated to research and development activities has remained stable in 2006 compared to 2005 and the company has invested $ 4.2 million on pre-clinical and clinical studies (decrease of $10.9 million compared with 2005).

     Costs of goods and services sold were $6.3 million in 2006, $2.5 million in 2005 and $3.6 million in 2004. These costs include direct and indirect labor, materials, outside services and overhead costs relevant to contract manufacturing provided to third parties at the Pessac facility. The fluctuation in costs year-to-year is the result of the de-emphasizing of contract manufacturing and services from 2004 through to October of 2005 and a focus of our production capabilities in 2006 towards the manufacture of commercial quantities of Coreg CR microparticles. Costs incurred during the course of 2006 represent both the costs of preparation and qualification of our facilities plus the cost of producing commercial quantities of the product for GSK.

     Selling, general and administrative (SG&A) expenses, amounted to $17.4 million in 2006, $14.5 million in 2005 and $7.6 million in 2004. SG&A expenses in 2006 include, $5.9 million of FAS 123R options-related expenses and in 2005 included a provision of $4.3 million resulting primarily from the consequences of the departure of the Chairman, CEO and founder of the Company and related parties. On a comparable basis, SG&A expenses have increased by $1.3 million mainly as a result of the increase in costs associated with patent registrations and execution of diligence associated with Sarbanes-Oxley 404. Increases in 2005 over 2004 SG&A expenses were largely attributable to the increase in personnel in business development and legal fees incurred by the proxy battle in June 2005.

     Non-Operating Items

     Interest income and realized gains on sale of monetary SICAVs (Sociétés d’Investissement à Capital Variable) was $2.0 million in 2006, $3.7 million in 2005 and $0.7 million in 2004. The significant decrease in interest income in 2006 is due to the realized gain on sale of monetary SICAVs in 2005 which had accumulated since 2003. In addition, fluctuating average cash balances invested year-to-year and variability of interest rates impact the level of interest earned and realized gains on sale of monetary SICAVs. Interest expense was $35,000 in 2006, $68,000 in 2005, and $45,000 in 2004 and is primarily related to the interest applicable to the Company’s equipment leases.

     Foreign exchange loss for 2006 amounted to $0.6 million compared to a gain of $0.5 million in 2005 and a loss of $0.2 million in 2004. These amounts are the consequence of having a significant volume of revenues denominated in USD and the corresponding variation in exchange rates during the year.

     Other income in 2006 consisted of a number of miscellaneous items as is the case in 2004. In 2005 other income consisted primarily of the termination fee from Bristol-Myers Squibb totaling $4.9 million executed in January 2005 relative to the licensing and commercialization agreement to develop and market Basulin.

     The French government provides tax credits to companies both for annual increased spending and annual volume of spending on innovative research and development. Income tax benefits correspond to these French research tax credits, which are credited against income taxes payable in each of the four years after being incurred or, if not so utilized, are recoverable in cash. As of December 31, 2006, Flamel had total research tax credits receivables of $12.2 million. If these credits are not applied against future income taxes, they will be received as cash payments in the fourth year after the credit is earned, i.e. $0.6 million in 2007, $4.9 million in 2008 , $4.5 million in 2009 and $2.2 million in 2010. The Company earned a research and development credit in 2006 of $2.1 million, $4.2 million in 2005 and $4.6 million in 2004. The reduction in the credit earned in 2006 is a direct result of the decrease in research and development costs in 2006 compared to 2005 and 2004.

     As of December 31, 2006, the Company had $89.6 million in French net operating loss carry-forwards. The above carry-forwards can be utilized against future operating income indefinitely.

     Net Income/Loss

     For the year ended December 31, 2006 the Company reported a net loss of $35.2 million or ($1.48) per share. For the year ended December 31, 2005, the Company reported a net loss of $27.4 million, or ($1.19) per share. For the year ended December 31, 2004, the Company reported a profit of $12.5 million, or $0.53 per share on a diluted basis and $0.58 per share (basic).

Liquidity and Capital Resources

     On December 31, 2006, the Company had $51.8 million in cash and cash equivalents and $10.9 million in marketable securities, as compared to $1.0 million and $82.8 million on December 31, 2005 and $4.6 million and $100.8 million on December 31, 2004. During the course of 2006, the Company transferred a significant volume of its resources to Short Term Fixed Deposits rather than marketable security investments in order to benefit from a higher return on investment. Consequently the level of cash and cash equivalents has increased as of December 31, 2006 compared to December 31, 2005 and the level of marketable securities decreased as of December 31, 2006 compared to December 31, 2005, over and above the cash used to finance operating activities.

     Net cash used in operating activities was ($30.3) million as of December 31, 2006, ($19.4) million as of December 31, 2005, and ($4.2) million as of December 31, 2004. As of December 31, 2006, net cash used in operating activities reflected net loss of $35.2 million offset by non-cash expenses totaling $13.6 million, including $5.2 million from depreciation of property and equipment and $10.0 million relative to stock compensation expenses. The increase in net cash used for operating activities compared with the period ended December 31, 2005 is principally the result of the variation in working capital year on year resulting in cash utilization of $8.7 million. The increase in accounts receivable and inventory of $2.6 million and $2.1 million respectively is a direct result of the commencement of manufacturing of commercial quantities of Coreg CR microparticles on behalf of GSK in the last quarter of 2006. In addition, payables relative to capital investments is lower at December 31, 2006, compared with December 31, 2005, due to the completion of the Micropump production facility in mid-2006 resulting in a reduction in accounts payables of $3.0 million.

     Net cash provided by investing activities was $73.1 million in 2006 and included proceeds from the sale of marketable securities amounting to $262.6 million, less $6.3 million primarily invested at the Pessac plant to provide production facilities for the manufacture of commercial quantities of Coreg CR microparticles and initial investments for the continued expansion of our facilities at Pessac, and $183.6 million relating to the purchase of marketable securities. The increase in net cash provided by investing activities is as a result of the transfer of certain of our investments from marketable securities to Short Term Fixed Deposits as discussed above. Net cash used in investing activities amounted to ($4.5) million in 2005 and net cash provided by investing activities amounted to $2.1 million in 2004.

     Net cash provided by financing activities was $5.5 million in 2006, which includes $5.0 million received from GSK to sponsor part of the extension of existing facilities which increases our production capacity from two lines to three, less $2.1 million used to invest in equipment on behalf of GSK, and $2.6 million resulting from the exercise of warrants from directors and the exercise of options from employees. In 2005 and 2004, financing activities provided $21.1 million and $5.1 million, respectively. In 2005, net cash provided by financing activities included $12.3 million received from GSK for the funding of investments less $7.9 million used to invest in equipment on behalf of GSK, plus $3.5 million of conditional grants received from government agencies and $13.6 million resulting from the exercise of warrants from investors and directors which yielded $9.4 million, and the exercise of options from employees which yielded $4.2 million. In 2004, net cash provided by financing activities includes $6.4 million received from GSK for the funding of investments, less $2.5 million which was used to invest in equipment, plus $0.8 million resulting from the exercise of options from employees.

     Since its inception, the Company’s operations date have consumed substantial amounts of cash and are expected to continue to do so in the short term. The Company believes that ongoing research and product development programs are adequately funded for the next year. The Company also believes current financial resources and cash from various grants, royalty payments and licenses will be sufficient to meet the Company’s cash requirements for at least the next two years.

     As of December 31, 2006, the Company held marketable securities classified as available-for-sale and recorded at fair value. Total marketable securities totaled $10.9 million at December 31, 2006 and $82.8 million at December 31, 2005.

     As of December 31, 2006, the Company had loans of $0.9 million from Anvar, an agency of the French government that provides financing to French companies for research and development and $1.9 million advance from the French Ministry of Industry for a ‘Proteozome research project’. These loans do not bear interest and are repayable only in the event that the research is successful technically or commercially. See Note 14 to the Consolidated Financial Statements.

     In addition, in 2004, Flamel and GlaxoSmithKline entered into a four year supply agreement whereby Flamel agreed to supply GlaxoSmithKline with commercial supplies of product. The provisions of the agreement include payments to Flamel of $20.7 million to support the costs and capital expenditure relative to the creation of a manufacturing area for the production of commercial supply of the product. The capital expenditure consists of both buildings and fixtures, and production equipment. Flamel will have immediate title to the building and fixtures and title to production equipment vests with GlaxoSmithKline for the duration of the supply agreement.

     If the Company breaches the supply agreement through gross negligence, GlaxoSmithKline can choose to terminate the supply agreement. The likely occurrence of this event is deemed remote given the Company’s ability to perform under supply arrangements based on our historical experience. In the event of a breach and a decision to terminate the agreement, all payments received become repayable to GlaxoSmithKline and Flamel will receive immediate title to all production equipment.

     Upon cessation of the supply agreement, in the normal course, GSK will pass title to all production equipment to Flamel without cost of any kind.

     As of December 31, 2006, Flamel had received all amounts payable by GSK under the agreement as detailed above. A total of $8.2 million has been spent on the acquisition of buildings and fixtures and a total of $11.1 million has been spent on behalf of GSK for the purchase of production equipment. As of December 31, 2006, all funds received have been used to purchase both equipment and facilities, for completion of the manufacturing area. The funds received from GSK to finance the acquisition of assets owned by Flamel are classified as a current liability for $0.9 million and as a long term liability for $7.1 million. The total liability of $7.1 million is being amortized on a pro-rata basis over the expected life of the related assets and reflected as an offset of the depreciation of the related assets.

     In July, 2006, the supply agreement was supplemented by an agreement with GSK to sponsor the expansion of our facilities at Pessac from two lines to three in anticipation of an expected increase in demand for the product. The provisions of the agreement include payments to Flamel of $7.2 million to partially support the acquisition of equipment, building and fixtures on which Flamel will have immediate title. GSK will have exclusive use of part of the facilities in order to meet demand requirements. At December 31, 2006, Flamel had received one installment for $5.3 million which is classified as a long term liability. The liability will be amortized on a pro-rata basis over the expected life of the related assets and reflected as a partial offset of the depreciation of the related assets.

     The Company does not maintain any credit lines with financial institutions.

     The contractual cash obligations of the Company are as follows

		Payments Due Per Period
						Less than				1 to 3				3 to 5				More than
(in thousands of US)		Total				1 year				years				years				5 years
Long-Term Debt (see note 14)		$	2,795							$	648			$	1,636			$	511
Capital Lease Obligation (see note 15)		$	713			$	437			$	276
Operating Leases (see note 21.2)		$	4,930			$	893			$	1,533			$	1,199			$	1,305
Total Contractual Cash Obligations		$	8,438			$	1,330			$	2,457			$	2,835			$	1,816

     As of December 31, 2006, the Company had ongoing purchase obligations for capital investments related to the extension of its facilities at Pessac amounting to $8.5 million. As of December 31, 2006, the Company has no off-balance sheet arrangements.

ITEM 6. Directors, Senior Management and Employees

Directors and Senior Management

     The following table sets forth the name and position of the directors of the Registrant as of December 31, 2006.

				Year of Initial
Name		Position		Appointment
Elie Vannier (1) (2)		Non-Executive Chairman of the Board of Directors			2005
Cor Boonstra (2)		Director			2005
Frédéric Lemoine (2) (3)		Director			2005
Lodewijk J.R. de Vink (1) (3)		Director			2006
John L. Vogelstein(1) (3)		Director			2005
Stephen H. Willard		Chief Executive Officer and Director			2000

     The following table sets forth the name and position of the executive officers and senior managers of the Registrant as of December 31, 2006.

				Year of Initial
Name		Position		Appointment
Michel Finance		Executive Vice President and Chief Financial Officer			2005
Rafael Jorda		Executive Vice President and Chief Operating Officer			1991
Andrew Francis		Vice President Business Development			2005
Christian Kalita		Directeur Général Délégué Pharmacien Responsable (Chief Pharmacist)			2005
Yves Bourboulou		Industrial Director			2005
Martine Capelle		Human Resources Director			2006
Catherine Castan		Director of R&D Micropump			1992
You Ping Chan		Director of Chemistry Department			1992
Sian Crouzet		Financial Controller			2005
Katherine Hanras		Director of Innovative Technologies			1998
Roger Kravtzoff		Preclinical and Early Clinical Development Director			2002
Kenneth Lundstrom		Director of Research			2006
Remi Meyrueix		Scientific Director			1990
Charles Mosseri-Marlio		Director of Strategic Planning and Investor Relations			2004
Raphaëlle Portella		Legal Counsel, France			2006
David Weber		Supply Chain Director			2004

     The term of office of each of the directors expires at the year 2007 ordinary shareholders meeting.

     In accordance with French law governing a société anonyme, the Company is managed by its Board of Directors and by its Directeur Général (Chief Executive Officer), who has full executive authority to manage the affairs of the Company, subject to the prior authorization of the Board of Directors or of the Company’s shareholders for certain decisions expressly specified by law. In addition, the Directeur Général may submit to the Board of Directors the nomination of one or more, but not more than five (5) Directeurs Généraux Délégués.

     The Board of Directors reviews and monitors Flamel’s economic, financial and technical strategies. In addition, under French law, the Board of Directors prepares and presents the year-end French statutory accounts of the Company to the shareholders and convenes shareholders’ meetings. French law provides that the Board of Directors be composed of no fewer than three and not more than 18 members, each of whom must be a shareholder of the Company. The actual number of directors must be within such limits and may be provided for in the statuts or determined by the shareholders at the annual general meeting of shareholders. The number of directors may be increased or decreased only by decision of the shareholders. No more than a third of directors may be over the age of seventy.

     Under French law, a director may be an individual or a legal entity. A legal entity that serves as a director must appoint an individual, as a ‘permanent representative,’ who represents such legal entity on the Board. There is no limitation, other than applicable age limits, on the number of terms that a director may serve. Directors are elected by the shareholders and serve until the expiration of their respective terms, or until their resignation, death or removal, with or without cause, by the shareholders. Vacancies which exist on the Board of Directors: (i) because of the resignation or death of a director, may be filled by the Board of Directors pending the next shareholders’ meeting, if the number of remaining directors after such resignation or death exceeds the minimum number of directors set forth in the Articles of Association; (ii) for whatever reason, must be filled by the Board of Directors within three months of such vacancy, if the number of remaining directors after such vacancy is less than the minimum number of directors set forth in the Articles of Association but exceeds the minimum legal requirement; and (iii) for whatever reason, must be filled immediately at a shareholders’ meeting if the number of directors after such vacancy is less than the minimum legal requirement.

     The Company’s Board of Directors currently consists of six members, five of whom are outside directors: Elie Vannier, Chairman of the Board of Directors and COO of Grandvision SA and Director of Promod SA; Cor Boonstra, former chairman and chief executive officer of Philips Electronics NV and Director of Hunton Douglas; Frédéric Lemoine, Chairman of the Supervisory Board of AREVA, former Deputy General Secretary of Economic Affairs to President Jacques Chirac of France, Director of Groupama SA and member of the Supervisory Board of Générale de Santé; Lodewijk J.R. de Vink, former President of Schering Plough International, former Chairman and Chief Executive Officer of Warner Lambert, Inc., Director of Alcon, Inc. and Director of Roche; and John L. Vogelstein, who is Senior Advisor of Warburg Pincus, former Vice Chairman of Warburg Pincus and Director of Mattel, Inc. We believe these directors bring broad experience to Flamel.

     Board Practices

     Non-Executive Directors of the Company receive fees for their services and are entitled to subscribe for warrants (as described in Note 17.3 to our Consolidated Financial Statements). Directors’ fees and warrants are proposed by the Board of Directors and are submitted for the approval of shareholders at the annual general shareholders’ meeting. Non-Executive directors are reimbursed, upon request, for expenses incurred in attending Board meetings.

     All directors are elected by the shareholders at each ordinary shareholders’ meeting approving the annual French statutory accounts of the Company. A quorum of the Board consists of one-half of the members of the Board of Directors, and actions are generally approved by a vote of the majority of the members present or represented by other members of the Board of Directors. The Chairman of the Board does not have the ability to cast a deciding vote in the event of a tie vote. A director may give a proxy to another director, but a director cannot represent more than one other director at any particular meeting. Members of the Board of Directors represented by another member at meetings do not count for purposes of determining the existence of a quorum.

     Directors are required to comply with applicable law and Flamel’s statuts. Under French law, directors are liable for violations of French legal or regulatory requirements applicable to ‘sociétés anonymes’, violation of the Company’s statuts or mismanagement. Directors may be held liable for such actions both individually and jointly with the other directors.

     French law requires that companies having at least 50 employees for a period of 12 consecutive months have a Comité d’Entreprise (Employee Representation Committee) composed of representatives elected from among the personnel. The Employee Representation Committee was formed in 1997. Two of those representatives are entitled to attend all meetings of the Board of Directors of the Company, but they do not have any voting rights.

     The Board has a Compensation Committee currently composed of Lodewijk J.R. de Vink (Chairman of the Committee), John L. Vogelstein and Elie Vannier. The Compensation Committee makes recommendations to the Board of Directors on the compensation of the executive officers of the Company, including the Chief Executive Officer. The Board of Directors takes the final decisions on compensation. The Board has an Audit Committee currently composed of Frédéric Lemoine (Chairman of the Committee), Cor Boonstra and Elie Vannier. The Audit Committee recommends to the Board the selection of Flamel’s independent auditors and reviews the findings of the auditors. The Company has a Nominating and Corporate Governance Committee, currently composed of John L.Vogelstein (Chairman of the Committee), Frédéric Lemoine and Lodewijk J.R. de Vink. The Company also has an informal Scientific Advisory Board.

     The Chief Executive Officer of Flamel has full executive authority to manage the affairs of Flamel and has broad powers to act on behalf of Flamel and to represent Flamel in dealings with third parties, subject only to those powers expressly reserved by law or corporate resolutions of the Board of Directors or the shareholders. The Chief Executive Officer determines, and is responsible for the implementation of the goals, strategies and budgets of Flamel, which are reviewed and monitored by the Board of Directors. The Board of Directors has the power to appoint and remove, at any time, the Chief Executive Officer.

     Compensation of Directors and Officers

     During 2006, the amount of compensation paid or accrued for the benefit of executive officers of the company and its subsidiaries for services in all capacities was $763,400 for Stephen H. Willard. In addition, Mr. Willard was granted options in the amount and on the terms set forth below, in the table showing options and warrants granted in 2006. In the event of termination of employment of Mr. Willard by the Company, other than for gross misconduct, Mr. Willard is entitled to receive an amount of $500,000. Executive directors do not receive compensation for their service in that capacity.

     On June 12^th 2006, a shareholders’ meeting approved a total amount of annual attendance fees allocated to the Board at 400,000 Euros. For the financial year 2006 a total amount of 478,333 Euros ($600,628) was paid or accrued for the benefit of non-executive for their services in that capacity.

     Senior Management and Executive Officers

The Company’s senior management includes the following individuals:

Stephen H. Willard is our Chief Executive Officer and also serves on our Board of Directors. Prior to being asked to serve in his present capacity by the Board of Directors in June of 2005, Mr. Willard was Flamel’s Chief Financial Officer and General Counsel. Immediately prior to joining us in August, 2000, Mr. Willard was employed as a vice president of Biovail. He also worked as an investment banker at Credit Suisse First Boston and as an attorney with Gibson, Dunn & Crutcher LLP and Shearman & Sterling LLP. He is a graduate of Yale Law School (1985) and Williams College (1982). He is a Director and Non Executive Vice Chairman of E-Trade Financial Corporation.

Michel Finance is our Chief Financial Officer and Executive Vice-President. He previously served as the Senior Vice President and Corporate Controller for Aventis Group, where he reported to the Vice-Chairman of the Board. He also worked as the Chief Financial Officer of Pasteur Mérieux Connaught (currently Sanofi Pasteur) from 1995 to 1999. He held before that various financial executive positions at Rhône Poulenc subsidiaries after having worked as an auditor at Coopers & Lybrand for five years. He is a graduate of EM Lyon and a French CPA.

Rafael Jorda is our Chief Operating Officer and Executive Vice President. Mr. Jorda joined us in 1991 and specializes in chemical engineering and in the structure-property relationships of materials. From 1986 to 1990, he worked as a research and development scientist on controlled-released and biopolymers at Rhone-Poulenc. He has a masters in Chemical Engineering from Virginia Tech. and is a graduate of Ecole Nationale Supérieure de Chimie de Montpellier.

Andrew Francis is our Vice-President in charge of Business Development. Prior to joining us in March of 2005, Mr. Francis served as Group Vice-President for Business Development at SkyePharma. A qualified pharmacist, Mr Francis has worked in the international healthcare industry for over thirty-five years in senior technical and commercial roles. He has been involved with the drug delivery sector since 1983 and has experience with a wide range of pharmaceutical technologies applied to virtually all routes of administration.

Christian Kalita is our Chief Pharmacist and Director of Quality Assurance and Regulatory Affairs . Mr Kalita worked previously at Skye Pharma as Director of Quality for Europe. He also worked from 1990 to 2000 for Merck Lipha and Merck generics in different roles as Chief Pharmacist, head of quality control management and Head of Industrial Affairs.

Yves Bourboulou is our Technical Director and Pessac Plant Deputy Manager. He worked previously as Plant manager at Pharmacia and Fresenius Kabi. He held before various senior pharmaceutical positions as Quality assurance Director; Chief Pharmacist. He has more than 20 years experience in pharmaceutical production; quality and development.

Martine Capelle is our Human Resources Director and joined us in 2006. She previously worked for the Danone group for 15 years in different Human Resource functions and roles and prior to this as Human Relations manager responsible for a couple of automobile plants. She is a graduate of Lyon Human Sciences University.

Catherine Castan is our Director of R&D Micropump. Mrs. Castan joined us in 1992 after having spent four years at Sanofi Recherche. She is a graduate of Ecole Nationale Supérieure de Chimie de Montpellier and has a PHD in polymer chemistry, applied in drug delivery.

You-Ping Chan is our Chemistry Department Director. Mr. Chan received his Ph. D in Chemistry from Université Louis Pasteur, Strasbourg in 1990. After spending a year as a post-doctoral associate at the Massachusetts Institute of Technology, he joined us in 1992 as a researcher in polymer science. He currently manages R&D in the field of biocompatible polymers for drug delivery and heads the analytical research group.

Sian Crouzet is our Controller. Mrs. Crouzet previously worked as Financial Controller France for McCormick & Company Inc. She also worked five years as an external auditor with Ernst and Young. She is a UK Chartered Accountant and a graduate of Bradford University.

Katherine Hanras is our Innovative Technologies Director and joined Flamel in 1998. Mrs. Hanras spent two years at the Lipid Institut (ITERG) working on Cell membranes and Biovector interactions and after joined Sarget Pharma as manager in the R&D analytical Department. In 1998, she obtained her PhD in pharmaceutical science/option Analytical Chemistry with a dissertation on natural polyphenolic plant extracts: structure-property relationships with skinhealing and cell apoptose.

Roger Kravtzoff is our Preclinical and Early Clinical Development Director. Mr. Kravtzoff received his Doctorat-es Sciences in Biochemistry from Tours University (France ) in 1988 and a broad expertise in drug delivery system. In 1985, he joined Centre Regional de Transfusion Sanguine as a research engineer, and in 1991, he became a scientist associate director in one of the subsidiaries of the French National Blood Center, Novacell. He joined Biovector Therapeutics in 1993 and worked as a Project Director. He joined us in June 2002 and is currently managing our regulatory affairs with regard to our pre-clinical and clinical developments.

Kenneth Lundstrom joined Flamel in June 2006 as Director of Research. Dr. Lundstrom is a molecular biologist by training and has acquired a broad expertise in protein expression, viral vectors, gene therapy, structural genomics and drug delivery. He has published more than 200 peer-reviewed research articles, reviews and book chapters. Previously, Dr. Lundstrom has worked for both big pharmaceutical companies and start-up biotechnology enterprises.

Remi Meyrueix is our Scientific Director. Mr. Meyrueix holds the degree of engineer in physics and a doctoral thesis in physics, which he received from the Polytechnic Institute of Grenoble in 1977 and 1980, respectively. He worked at Rhone Poulenc from 1982 to 1990 and joined us in early 1991 as a research engineer. He is now managing the Nanotechnology platform in Venissieux, France.

Charles Mosseri-Marlio is our Director of Strategic Planning and Investor Relations, having previously served as Associate General Counsel. Mr. Mosseri-Marlio joined us in 2004 after working as a portfolio manager of Baldwin Brothers, Inc, a U.S. Investment Advisory firm. Mr. Mosseri-Marlio received his JD in 1994 from the University of Colorado.

Raphaëlle Portella is our French Legal in-house Counsel and joined us in April 2006. Mrs Portella previously worked as Head of the Corporate and Business Law Department for ADIA (Adecco Group) for almost 10 years. She graduated from Lyon University with a master (DESS) in Business Law.

David Weber is our Supply Chain Director. He has more than 10 years experience in purchasing and operations management at various international companies including Garrett (Honeywell group) and Isringhausen. Before joining us he was Vice President and Cofounder of Pertinence Data Intelligence.

     Options to Purchase Securities from the Company

     On May 10, 1996, the shareholders of the Company authorized the creation of a share option plan (the ‘1996 Plan’), which authorizes the Board of Directors to issue options to subscribe for up to 1,000,000 Shares. The 1996 Plan is designed to permit the granting of ‘qualifying stock options’ under French tax law principles as well as ‘incentive stock options’ under the U.S. Internal Revenue Code of 1986, as amended. Options granted under the 1996 Plan will have an exercise price of not less than ninety percent (90%) of the fair market value of a Share on the date of grant, based on the closing price of the ADSs on the NASDAQ National Market on that date, after converting the dollar closing price into Euros at the Noon Buying Rate on the date of grant. The difference between the market price and the granted price is recognized as a compensation expense. The options granted under the 1996 Plan are exercisable up to ten years from the date of grant. Under French law, the Company cannot grant options to members of the Board of Directors who are not employees.

     On July 19, 2001, the Company issued to each of Messrs. Meredith and Treilles, each a member of the Board of Directors of the Company, 10,000 warrants. Each warrant is exercisable to purchase one Share at a price of 5.94 Euros ($5.24) ² per share.

     On December 19, 2001, the shareholders of the Company authorized the creation of a share option plan (the ‘2001 Plan’), which authorizes the Board of Directors to issue options to subscribe for up to 750,000 Shares. The 2001 Plan is designed to permit the granting of ‘qualifying stock options’ under French tax law principles as well as ‘incentive stock options’ under the Internal Revenue Code of 1986, as amended. Options granted under the 2001 Plan will have an exercise price based on the fair market value of a Share on the date of grant, i.e. the closing price of the ADSs on the NASDAQ National Market the day prior to the date of the grant, converted into Euros using the exchange rate published by Banque de France on the day preceding the date of the grant. The options granted under the 2001 Plan are exercisable up to ten years from the date of grant.

     On June 20, 2002, the Company issued to each of Messrs. Meredith and Treilles, each a member of the Board of Directors of the Company, 40,000 warrants. Each warrant is exercisable to purchase one Share at a price of 2.33 Euros ($2.05) ² per share.

     On September 19, 2002, the Company issued to Mr. Compain, a member of the Board of Directors of the Company, 40,000 warrants. Each warrant is exercisable to purchase one Share at a price of 1.36 Euros ($1.35)² per share.

     On February 18, 2003, the shareholders of the Company authorized the creation of a share option plan (the ‘2003 Plan’), which authorizes the Board of Directors to issue options to subscribe for up to 900,000 Shares. The 2003 Plan is designed to permit the granting of ‘qualifying stock options’ under French tax law principles as well as ‘incentive stock options’ under the Internal Revenue Code of 1986, as amended. Options granted under the 2003 Plan will have an exercise price based on the fair market value of a Share on the date of grant, i.e. the closing price of the ADSs on the NASDAQ National Market the day prior the date of the grant, converted into Euros using the exchange rate published by Banque de France on the day preceding the date of the grant. The options granted under the 2003 Plan are exercisable up to ten years from the date of grant.

     On November 7, 2003, the shareholders of the Company authorized the creation of a share option plan (the ‘2004 Plan’), which authorizes the Board of Directors to issue options to subscribe for up to 1,000,000 Shares. The 2004 Plan is designed to permit the granting of ‘qualifying stock options’ under French tax law principles as well as ‘incentive stock options’ under the Internal Revenue Code of 1986, as amended. Options granted under the 2004 Plan will have an exercise price based on the fair market value of a Share on the date of grant, i.e. the closing price of the ADSs on the NASDAQ National Market the day prior the date of the grant, converted into Euros using the exchange rate published by Banque de France on the day preceding the date of the grant. The options granted under the 2004 Plan are exercisable up to ten years from the date of grant.

     On November 7, 2003, the Company issued to the Directors of the Company, Mssrs. Cesan, Greco and Dearstyne 60,000 warrants each. For Mr. Treilles, member of the Board since March 2000, the Company issued 20,000 warrants. Each warrant is exercisable to purchase one Share at a price of 9.88 Euros ($11.29) ².

     On March 4, 2005, the shareholders of the Company authorized the creation of a share option plan (the ‘2005 Plan’), which authorizes the Board of Directors to issue options to subscribe for up to 1,500,000 Shares. The 2005 Plan is designed to permit the granting of ‘qualifying stock options’ under French tax law principles as well as ‘incentive stock options’ under the Internal Revenue Code of 1986, as amended. Options granted under the 2005 Plan will have an exercise price based on the market price of the share, in the form of ADS, on NASDAQ, on the day preceding the date of the Board meeting, provided however, that such price is not less than 80% of the average market price for the shares on the NASDAQ, in the form of ADSs, during the last twenty trading days preceding said meeting. In this case, the price of the shares should be equal or superior to 80% of the average market price for the share on NASDAQ, in the form of ADS, during the last twenty trading days preceding such meeting. Such minimum price is the price applicable to companies, the shares of which are admitted to negotiation on a regulated market. The options granted under the 2005 Plan are exercisable up to ten years from the date of grant.

     On October 24, 2005, the shareholders of the Company authorized the issuance of up to 250,000 warrants reserved to a category of beneficiaries comprising the Directors of the Company who are not officers and/or employees of the Company, including the Chairman, of which 240,000 have been subscribed for. On November 3, 2005, the Board of Directors authorized the Directors of the Company, Mssrs. Vogelstein, Boonstra, Thurmann and Lemoine, to subscribe to 60,000 warrants each for a subscription price of 1.49 Euros per warrant ($1.79) ². Each warrant is exercisable to purchase one Share at price of 14.91Euros ($17.88) ².

     On March 2, 2006, the Board of Directors authorized Mr. Lodewijk J.R. de Vink, Director, to subscribe to 63,084 warrants and Mssrs Boonstra and Vogelstein to subscribe for 3,083 warrants each for a subscription price of 2.0 Euros per warrant ($2.40) ². Each warrant is exercisable to purchase one Share at price of 20.07 Euros ($23.99)².

     On October 24, 2005, the shareholders of the Company authorized the issuance of new shares which authorizes the Board of Directors to award and issue up to 200,000 shares free of charge to officers and employees of the company as compensation for services rendered. Under the terms of the awards the shares are definitively owned by the beneficiaries two years following their allocation and the beneficiaries are required to retain the shares for a further two years.

     On June 12, 2006, the shareholders of the Company authorized the issuance of up to 150,000 warrants reserved to a category of beneficiaries comprising the Directors of the Company who are not officers and/or employees of the Company, including the Chairman, of which 125,000 have been subscribed for.

     On June 12, 2006, the Board of Directors authorized the Directors of the Company, Mssrs., Boonstra, de Vink, Lemoine, Vannier and Vogelstein, to subscribe to 25,000 warrants each for a subscription price of 1.46 Euros per warrant ($1.84) ². Each warrant is exercisable to purchase one Share at a price of 14.6 Euros ($18.48)².

Options and Free of Charge Share Awards Granted and Warrants Subscribed from January 1, 2006
to March 31, 2007

																										Free of
						Number				Plan on				Exercise				Exercise								Charge
						of				Which				Price in				Price in								Share
		Warrants				Options				Granted				Euros €				USD $2				Expiration				Awards
Vannier			25,000												14.60				18.48			June 2009
Boonstra			60,000												14.91				17.88			November 2008
			3,083												20.07				23.99			March 2009
			25,000												14.60				18.48			June 2009
De Vink			63,084												20.07				23.99			March 2009
			25,000												14.60				18.48			June 2009
Lemoine			50,750												14.91				17.88			November 2008
			25,000												14.60				18.48			June 2009
Vogelstein			60,000												14.91				17.88			November 2008
			3,083												20.07				23.99			March 2009
			25,000												14.60				18.48			June 2009
Willard							100,000				2004				25.39				33.46			December 2016
Alluis							1,000				2004				16.56				20.4			April 2016					1,500
Angot																											1,500
Autant							3,250				2005				25.39				33.46			December 2016					2,450
Bardet							2,000				2005				25.39				33.46			December 2016					1,500
Bourboulou							6,500				2005				25.39				33.46			December 2016					5,000
Borel							2,750				2005				25.39				33.46			December 2016					2,000
Caisse																											1,700
Capelle							25,000				2004				13.97				17.65			July 2016
							3,750				2005				25.39				33.46			December 2016					2,800
Castan							6,000				2005				25.39				33.46			December 2016					4,500
Chan							4,500				2005				25.39				33.46			December 2016					3,300
Commaret							3,250				2005				25.39				33.46			December 2016					2,400
Crouzet							3,750				2005				25.39				33.46			December 2016					2,800
Fernandez							3,750				2005				25.39				33.46			December 2016					2,800
Finance							30,000				2005				25.39				33.46			December 2016					2,500
Gorria							20,000				2005				20.07				23.99			April 2016
							4,000				2005				25.39				33.46			December 2016					3,500
Guest							20,000				2005				25.39				33.46			December 2016
Guimberteau							3,750				2005				25.39				33.46			December 2016					2,800
Jorda							53,500				2004				25.39				33.46			December 2016
							6,500				2005				25.39				33.46			December 2016					5,000
Kalita							6,500				2005				25.39				33.46			December 2016					5,000
Kravtzoff							4,500				2005				25.39				33.46			December 2016					3,300
Lemercier							10,000				2005				20.07				23.99			March 2016
							2,000				2005				25.39				33.46			December 2016					1,500
Lundstrom							100,000				2005				16.56				20.40			June 2016
Marlio							2,250				2005				25.39				33.46			December 2016					1,700
McWilliam							10,000				2005				25.39				33.46			December 2016
Meyrueix							7,250				2005				25.39				33.46			December 2016					5,400
Nicolas							2,400				2005				25.39				33.46			December 2016					1,750
Portella							2,750				2005				25.39				33.46			December 2016					2,000
Prevot							2,750				2005				25.39				33.46			December 2016					2,000
Thomas																											1,500
Vialas							20,000				2005				20.07				23.99			March 2016
							2,350				2005				25.39				33.46			December 2016					1,750
Weber							2,750				2005				25.39				33.46			December 2016					2,000

     Employees

     As of December 31, 2006, Flamel had 306 full-time employees. The following table sets forth the number of employees for each of the last three years based in their principal geographic locations.

Employees

		Venissieux (1)				Pessac (2)				USA (3)				Total
Year End
2004			120				101				3				224
2005			123				131				5				259
2006			128				174				4				306

     The Company’s future will depend on its ability to attract and retain highly qualified personnel. The Company believes that its employee relations are good. As required by French law, the Company has created an Employee Representation Committee (‘Comite d’Entreprise’) composed of representatives elected from among the personnel. Two of these representatives are entitled to attend certain meetings of the Board of Directors of the Company, but they do not have any voting rights.

     Share Ownership

     The following table sets forth the share ownership of directors, executive officers and senior managers as of the date indicated:

OWNERSHIP OF SHARES AS OF APRIL 20, 2007

																		Exercise				Exercise
						% of Ordinary												Price in				Price in USD
		Shares				Shares								Number of				Euros				(2)										Total
Name		Owned				Outstanding				Warrants				Options				€				$				Expiration		Total				%
Vannier			1				0,00	%							75 000				13,72				16,68			September 2008
											25 000								14,6				18,48			June 2009			100 001				0,35	%
Boonstra			1				0,00	%			60 000								14,91				17,88			November 2008
											3 083								20,07				23,99			March 2009
											25 000								14,6				18,48			June 2009			88 084				0,31	%
De Vink			1				0,00	%			63 084								20,07				23,99			March 2009
											25 000								14,6				18,48			June 2009			88 085				0,31	%
Lemoine			1				0,00	%			30 750								14,91				17,88			November 2008
											25 000								14,6				18,48			June 2009			55 751				0,20	%
Vogelstein			100 001				0,42	%			60 000								14,91				17,88			November 2008
											3 083								20,07				23,99			March 2009
											25 000								14,6				18,48			June 2009			188 084				0,66	%
Willard			40 001				0,17	%							40 000				7,58				4,99			September 2010
															40 000				6,4				5,73			December 2010
															25 000				6,4				5,73			December 2010
															50 000				1,09				0,99			September 2011
															195 000				2,33				2,04			March 2012
															200 000				4,32				4,62			March 2013
															100 000				20,81				25,27			December 2013
															150 000				14,81				19,70			December 2014
															100 000				16,23				19,35			December 2015
															100 000				25,39				33,46			December 2016			1 040 001				3,66	%

OWNERSHIP OF SHARES AS OF APRIL 20, 2007 continued

																		Exercise				Exercise						Free of
						% of Ordinary												Price in				Price in USD						Charge
		Shares				Shares								Number of				Euros				(2)						Share				Total
Name		Owned				Outstanding				Warrants				Options				€				$				Expiration		Awards			Total		%
Bourboulou							0,00	%							50 000				13,08				17,49			May 2015
															20 000				12,86				15,83			September 2015
															6 500				25,39				33,46			December 2016		5 000			81 500		0,29	%
Capelle							0,00	%							25 000				13,97				17,65			June 2016
															3 750				25,39				33,46			December 2016		2 800			31 550		0,11	%
Castan							0,00	%							3 000				1,09				0,99			September 2011
															5 000				9,88				11,66			June 2013
															40 000				20,81				25,27			December 2013
															20 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015
															6 000				25,39				33,46			December 2016		4 500			98 500		0,35	%
Chan							0,00	%							5 000				9,88				11,66			June 2013
															20 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015
															4 500				25,39				33,46			December 2016		3 300			52 800		0,19	%
Crouzet							0,00	%							50 000				12,86				15,83			September 2015
															5 000				16,23				19,35			December 2015
															3 750				25,39				33,46			December 2016		2 800			61 550		0,22	%
Finance															200 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015
															30 000				25,39				33,46			December 2016		2 500			252 500		0,89	%
Francis							0,00	%							100 000				11,42				15,24			March 2015
															30 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015					150 000		0,53	%
Hanras							0,00	%							5 000				9,88				11,66			June 2013
															40 000				20,81				25,27			December 2013					45 000		0,16	%
Jorda			369				0,00	%							50 000				2,78				2,49			December 2011
															5 000				9,88				11,66			June 2013
															60 000				14,81				19,70			December 2014
															105 000				12,86				15,83			September 2015
															75 000				16,23				19,35			December 2015
															60 000				25,39				33,46			December 2016		5 000			360 369		1,27	%
Kalita							0,00	%							50 000				16,23				19,35			December 2015
															6 500				25,39				33,46			December 2016		5 000			61 500		0,22	%
Kravtzoff			400				0,00	%							40 000				1,36				1,34			June 2012
															5 000				9,88				11,66			June 2013
															30 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015
															4 500				25,39				33,46			December 2016		3 300			103 200		0,36	%
Lundstrom							0,00	%							100 000				16,56				20,40			June 2016					100 000		0,35	%
Meyrueix			125				0,00	%							40 000				4,87				4,65			April 2010
															40 000				2,78				2,49			December 2011
															5 000				9,88				11,66			June 2013
															40 000				14,81				19,70			December 2014
															30 000				12,86				15,83			September 2015
															20 000				16,23				19,35			December 2015
															7 250				25,39				33,46			December 2016		5 400			187 775		0,66	%